<SEC-DOCUMENT>0001193125-14-161143.txt : 20140428
<SEC-HEADER>0001193125-14-161143.hdr.sgml : 20140428
<ACCEPTANCE-DATETIME>20140428071806
ACCESSION NUMBER:		0001193125-14-161143
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20140428
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140428
DATE AS OF CHANGE:		20140428

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOGENEX PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0000949858
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				954343413
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	033-80623
		FILM NUMBER:		14787394

	BUSINESS ADDRESS:	
		STREET 1:		1522 217TH PLACE S.E.
		CITY:			BOTHELL
		STATE:			WA
		ZIP:			98021
		BUSINESS PHONE:		4254879500

	MAIL ADDRESS:	
		STREET 1:		1522 217TH PLACE S.E.
		CITY:			BOTHELL
		STATE:			WA
		ZIP:			98021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SONUS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19950825
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d713590d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): April&nbsp;28, 2014 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>ONCOGENEX PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>033-80623</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>95-4343413</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1522 217th Place S.E.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Bothell, Washington</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>98021</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of Principal Executive Offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (425)&nbsp;487-9500 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or
former address if changed since last report.) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Results of Operations and Financial Condition. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;28, 2014, OncoGenex
Pharmaceuticals, Inc. (the &#147;Company&#148;) announced results from the Phase 3 SYNERGY trial. Top-line survival results indicate that the addition of custirsen to standard first-line docetaxel/prednisone therapy did not meet the primary endpoint
of a statistically significant improvement in overall survival in men with metastatic castrate-resistant prostate cancer, compared to docetaxel/prednisone alone (median survival 23.4 months vs 22.2 months, respectively; hazard ratio 0.93 and
one-sided p value 0.207). Copies of the Company&#146;s press release and the Company&#146;s joint press release with Teva Pharmaceutical Industries Ltd. are filed as Exhibits&nbsp;99.1 and 99.2, respectively, to this Current Report on Form 8-K. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Exhibits </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:37.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B></B>Exhibit&nbsp;No.<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman"><B></B>Description<B></B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center">99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press release issued by OncoGenex Pharmaceuticals, Inc. dated April 28, 2014</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center">99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press release issued by Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. dated April 28, 2014</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">ONCOGENEX PHARMACEUTICALS, INC.</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: April&nbsp;28, 2014</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Susan Wyrick</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Susan Wyrick</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice President, Finance</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Principal Accounting Officer)</P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="44%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center">99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Press release issued by OncoGenex Pharmaceuticals, Inc. dated April 28, 2014</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center">99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Press release issued by Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. dated April 28, 2014</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d713590dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OncoGenex Announces Top-Line Survival Results of Phase 3 SYNERGY Trial Evaluating Custirsen for Metastatic Castrate-Resistant Prostate
Cancer </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bothell, WA and Vancouver, BC, April&nbsp;28, 2014</B> &#150; OncoGenex Pharmaceuticals, Inc. <B>(NASDAQ: OGXI)</B> today announced results
from the Phase 3 SYNERGY trial. Top-line survival results indicate that the addition of custirsen to standard first-line docetaxel/prednisone therapy did not meet the primary endpoint of a statistically significant improvement in overall survival in
men with metastatic castrate-resistant prostate cancer (CRPC), compared to docetaxel/prednisone alone (median survival 23.4 months vs 22.2 months, respectively; hazard ratio 0.93 and one-sided p value 0.207). The adverse events observed were similar
to custirsen&#146;s known adverse event profile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The results of SYNERGY are unexpected, particularly given the wealth of scientific evidence
supporting the targeting of clusterin to combat treatment resistance in first-line prostate cancer,&#148; said Scott Cormack, President and CEO of OncoGenex. &#147;A thorough analysis of the data is underway to understand the potential factors that
may have contributed to the results. Importantly, we remain strong in our belief that targeting mechanisms of treatment resistance is a critical path forward in the fight against cancer and we continue to actively pursue this approach through the
two ongoing Phase 3 trials of custirsen and the seven Phase 2 trials of apatorsen in four tumor types. We would like to thank the men who participated in the SYNERGY trial and the friends and families who supported them.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OncoGenex will host a conference call and live webcast at 7:30 a.m. ET&nbsp;this morning. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To access the webcast, log on to the Investor Relations page of the OncoGenex website at&nbsp;<U>www.oncogenex.com</U>. Alternatively, you may access the live
conference call by dialing (877)&nbsp;606-1416&nbsp;(U.S. &amp;&nbsp;Canada) or&nbsp;(707) 287-9313&nbsp;(International). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A webcast replay will be
available approximately two hours after the call and will be archived on&nbsp;<U>www.oncogenex.com</U>&nbsp;for 90 days. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>About Custirsen
</U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Custirsen is an experimental drug that is designed to block the production of the protein clusterin, which may play a fundamental role in cancer
cell survival and treatment resistance. Clusterin is upregulated in tumor cells in response to treatment interventions such as chemotherapy, hormone ablation and radiation therapy and has been found to be overexpressed in a number of cancers,
including prostate, lung, breast and bladder. Increased clusterin production has been linked to faster rates of cancer progression, treatment resistance and shorter survival duration. By inhibiting clusterin, custirsen is designed to alter tumor
dynamics, slowing tumor growth and resistance to partner treatments, so that the benefits of therapy, including survival, may be extended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of
Phase 1 and Phase 2 clinical trials, custirsen was administered to 294 patients with various types of cancer. The majority of adverse events were mild. The most common adverse events associated with custirsen consisted of flu-like symptoms. The most
common serious adverse events (SAE) associated with custirsen were febrile neutropenia, fever, pleural effusion, and dyspnea. Each SAE event was observed in approximately 2%-4% of patients. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>About SYNERGY </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SYNERGY trial enrolled 1,022 men with mCRPC at more than 130 cancer centers throughout North America, Europe, Israel and South Korea. In the
investigational arm of the trial, custirsen was administered as a weekly infusion of 640 mg following three loading doses, in combination with docetaxel and prednisone given as standard 3-week cycles. Patients in the active comparator arm received
docetaxel and prednisone without custirsen. In both arms, patients were treated until disease progression, unacceptable toxicity, or completion of up to 10 cycles, unless additional cycles were deemed beneficial. Full efficacy and safety data from
SYNERGY will be submitted for presentation at an upcoming scientific conference. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>About OncoGenex </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer
patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex&nbsp;and&nbsp;Teva Pharmaceutical Industries Ltd.
have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex&#146; lead drug candidate, custirsen. Custirsen utilizes second-generation antisense technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS), to
effectively target and inhibit production of clusterin. OncoGenex and Isis partnered in the successful discovery of custirsen and in its initial development. Custirsen is currently in Phase 3 clinical development as a treatment in men with
metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development. More information is available at
www.OncoGenex.com and at the company&#146;s Twitter account: <U>https://twitter.com/OncoGenex_IR</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I></I><B>OncoGenex&#146; Forward Looking
Statements</B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I></I><B></B><I>This press release contains forward-looking statements within the meaning of the &#147;safe harbor&#148; provisions
of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning the potential benefits of our product candidates. All statements other than statements of historical fact are statements that could be
deemed forward-looking statements. These statements are based on management&#146;s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those
described in the forward-looking statements, including, among others, the risk that our product candidates will not demonstrate the hypothesized or expected benefits, the risk of delays in our expected clinical trials and the other factors described
in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including the Company&#146;s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update
the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Media Contact: </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Jaime Welch </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>jwelch@oncogenex.com </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>604-630-5403 </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investor Relations Contact: </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Susan Specht </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>sspecht@oncogenex.com</U> </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>425-686-1535 </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d713590dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g713590img1.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Teva and OncoGenex Announce Top-Line Survival Results of Phase III SYNERGY Trial Evaluating Custirsen in
Combination with First-line Docetaxel and Prednisone for Metastatic Castrate-Resistant Prostate Cancer </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Jerusalem; Vancouver, BC; and Bothell, WA,
April&nbsp;28, 2014</B> &#150; Teva Pharmaceutical Industries Ltd. <B>(NYSE: TEVA)</B> and OncoGenex Pharmaceuticals, Inc. <B>(NASDAQ: OGXI)</B> today announced results from the Phase III SYNERGY trial, a randomized, open-label, two-arm study
comparing the combination of custirsen and standard first-line docetaxel/prednisone therapy to docetaxel/prednisone alone in men with metastatic castrate-resistant prostate cancer (CRPC). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Top-line survival results indicate the addition of custirsen to standard first-line docetaxel/prednisone therapy did not meet the primary endpoint of a
statistically significant improvement in overall survival (OS) in men with metastatic CRPC, compared to docetaxel/prednisone alone (median survival 23.4 months vs 22.2 months, respectively; hazard ratio 0.93 and one-sided p-value 0.207). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are disappointed with these results. Addressing treatment resistance is critical in the fight against cancer. We are working with OncoGenex to more
fully understand these data,&#148; said Michael Hayden, MD, president of global R&amp;D and chief scientific officer at Teva Pharmaceutical Industries Ltd. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The adverse events (AEs) observed for custirsen were similar to its known AE profile. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Full efficacy and safety data from SYNERGY will be submitted for presentation at an upcoming scientific conference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>About Custirsen </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Custirsen is an experimental drug
that is designed to block the production of the protein clusterin, which may play a fundamental role in cancer cell survival and treatment resistance. Clusterin is upregulated in tumor cells in response to treatment interventions such as
chemotherapy, hormone ablation and radiation therapy and has been found to be overexpressed in a number of cancers, including prostate, lung, breast and bladder. Increased clusterin production has been linked to faster rates of cancer progression,
treatment resistance and shorter survival duration. By inhibiting clusterin, custirsen is designed to alter tumor dynamics, slowing tumor growth and resistance to partner treatments, so that the benefits of therapy, including survival, may be
extended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of Phase 1 and Phase 2 clinical trials, custirsen was administered to 294 patients with various types of cancer. The majority of
adverse events were mild. The most common adverse events associated with custirsen consisted of flu-like symptoms. The most common serious adverse events (SAE) associated with custirsen were febrile neutropenia, fever, pleural effusion, and dyspnea.
Each SAE event was observed in approximately 2%-4% of patients. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>


<TR>
<TD HEIGHT="16" STYLE="BORDER-TOP:1.50pt solid #000000">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2" STYLE="BORDER-TOP:1.50pt solid #000000">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2" STYLE="BORDER-TOP:1.50pt solid #000000">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2" STYLE="BORDER-TOP:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">IR Contacts:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>Kevin C. Mannix</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">United States</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">(215) 591-8912</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ran Meir</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tomer Amitai</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Susan Specht, OncoGenex </B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>United States</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Israel</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">United States</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(215) 591-3033</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">972 (3) 926-7656</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(425) 686-1535</P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PR Contacts:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>Iris Beck Codner </B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">Israel</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">972 (3) 926-7687</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Denise Bradley</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nancy Leone</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Jaime Welch, OncoGenex</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United States</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United States</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">United States</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(215) 591-8974</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(215) 284-0213</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(604) 630-5403</P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g713590img1.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>About Teva </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by
developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world&#146;s leading generic drug maker, with a global
product portfolio of more than 1,000 molecules and a direct presence in approximately 60 countries. Teva&#146;s branded businesses focus on CNS, oncology, pain, respiratory and women&#146;s health therapeutic areas as well as biologics. Teva
currently employs approximately 45,000 people around the world and reached $20.3 billion in net revenues in 2013. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>About OncoGenex </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer
patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex&nbsp;and&nbsp;Teva Pharmaceutical Industries Ltd.
have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex&#146; lead drug candidate, custirsen. Custirsen utilizes second-generation antisense technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS), to
effectively target and inhibit production of clusterin. OncoGenex and Isis partnered in the successful discovery of custirsen and in its initial development. Custirsen is currently in Phase 3 clinical development as a treatment in men with
metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development. More information is available at
www.OncoGenex.com and at the company&#146;s Twitter account: <U>https://twitter.com/OncoGenex_IR</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>OncoGenex&#146; Forward Looking Statements
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains forward-looking statements within the meaning of the &#147;safe harbor&#148; provisions of the Private Securities
Litigation Reform Act of 1995, including, but not limited to, statements concerning the potential benefits of our product candidates. All statements other than statements of historical fact are statements that could be deemed forward-looking
statements. These statements are based on management&#146;s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the
forward-looking statements, including, among others, the risk that our product candidates will not demonstrate the hypothesized or expected benefits, the risk of delays in our expected clinical trials and the other factors described in our risk
factors set forth in our filings with the Securities and Exchange Commission from time to time, including the Company&#146;s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update the
forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>
<TR>
<TD HEIGHT="16" STYLE="BORDER-TOP:1.50pt solid #000000">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2" STYLE="BORDER-TOP:1.50pt solid #000000">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2" STYLE="BORDER-TOP:1.50pt solid #000000">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2" STYLE="BORDER-TOP:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">IR Contacts:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>Kevin C. Mannix</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">United States</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">(215) 591-8912</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ran Meir</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tomer Amitai</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Susan Specht, OncoGenex </B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>United States</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Israel</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">United States</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(215) 591-3033</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">972 (3) 926-7656</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(425) 686-1535</P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PR Contacts:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>Iris Beck Codner </B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">Israel</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">972 (3) 926-7687</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Denise Bradley</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nancy Leone</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Jaime Welch, OncoGenex</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United States</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United States</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">United States</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(215) 591-8974</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(215) 284-0213</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(604) 630-5403</P></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g713590img1.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Teva&#146;s Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995:
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This release contains forward-looking statements, which are based on management&#146;s current beliefs and expectations and involve a number of
known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important
factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialize additional pharmaceutical products; competition for our innovative products, especially COPAXONE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (including competition from orally-administered alternatives, as well as from potential purported generic equivalents); the possibility of material fines, penalties and other sanctions and other
adverse consequences arising out of our ongoing FCPA investigations and related matters; our ability to achieve expected results from the research and development efforts invested in our pipeline of specialty and other products; our ability to
reduce operating expenses to the extent and during the timeframe intended by our cost reduction program; our ability to identify and successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate
acquisitions; the extent to which any manufacturing or quality control problems damage our reputation for quality production and require costly remediation; our potential exposure to product liability claims that are not covered by insurance;
increased government scrutiny in both the U.S. and Europe of our patent settlement agreements; our exposure to currency fluctuations and restrictions as well as credit risks; the effectiveness of our patents, confidentiality agreements and other
measures to protect the intellectual property rights of our specialty medicines; the effects of reforms in healthcare regulation and pharmaceutical pricing, reimbursement and coverage; governmental investigations into sales and marketing practices,
particularly for our specialty pharmaceutical products; uncertainties related to our recent management changes; the effects of increased leverage and our resulting reliance on access to the capital markets; any failure to recruit or retain key
personnel, or to attract additional executive and managerial talent; adverse effects of political or economical instability, major hostilities or acts of terrorism on our significant worldwide operations; interruptions in our supply chain or
problems with internal or third-party information technology systems that adversely affect our complex manufacturing processes; significant disruptions of our information technology systems or breaches of our data security; competition for our
generic products, both from other pharmaceutical companies and as a result of increased governmental pricing pressures; competition for our specialty pharmaceutical businesses from companies with greater resources and capabilities; decreased
opportunities to obtain U.S. market exclusivity for significant new generic products; potential liability in the U.S., Europe and other markets for sales of generic products prior to a final resolution of outstanding patent litigation; any failures
to comply with complex Medicare and Medicaid reporting and payment obligations; the impact of continuing consolidation of our distributors and customers; significant impairment charges relating to intangible assets and goodwill; potentially
significant increases in tax liabilities; the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business; variations in patent laws that may adversely affect our
ability to </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>
<TR>
<TD HEIGHT="16" STYLE="BORDER-TOP:1.50pt solid #000000">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2" STYLE="BORDER-TOP:1.50pt solid #000000">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2" STYLE="BORDER-TOP:1.50pt solid #000000">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2" STYLE="BORDER-TOP:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">IR Contacts:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>Kevin C. Mannix</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">United States</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">(215) 591-8912</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ran Meir</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tomer Amitai</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Susan Specht, OncoGenex </B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>United States</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Israel</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">United States</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(215) 591-3033</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">972 (3) 926-7656</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(425) 686-1535</P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PR Contacts:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>Iris Beck Codner </B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">Israel</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">972 (3) 926-7687</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Denise Bradley</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nancy Leone</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Jaime Welch, OncoGenex</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United States</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United States</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">United States</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(215) 591-8974</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(215) 284-0213</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(604) 630-5403</P></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g713590img1.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>
manufacture our products in the most efficient manner; environmental risks; and other factors that are discussed in our Annual Report on Form 20-F for the year ended December&nbsp;31, 2013 and in
our other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and we assume no obligation to update or revise any forward-looking statement, whether as a result of new
information, future events or otherwise. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>
<TR>
<TD HEIGHT="16" STYLE="BORDER-TOP:1.50pt solid #000000">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2" STYLE="BORDER-TOP:1.50pt solid #000000">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2" STYLE="BORDER-TOP:1.50pt solid #000000">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2" STYLE="BORDER-TOP:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">IR Contacts:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>Kevin C. Mannix</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">United States</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">(215) 591-8912</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ran Meir</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tomer Amitai</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Susan Specht, OncoGenex </B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>United States</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Israel</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">United States</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(215) 591-3033</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">972 (3) 926-7656</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(425) 686-1535</P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PR Contacts:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>Iris Beck Codner </B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">Israel</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">972 (3) 926-7687</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Denise Bradley</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nancy Leone</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Jaime Welch, OncoGenex</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United States</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United States</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">United States</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(215) 591-8974</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(215) 284-0213</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(604) 630-5403</P></TD></TR></TABLE>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g713590img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713590img1.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`8@+&`P$1``(1`0,1`?_$`.T``0`!`P4!`0``````
M```````)!P@*`0(#!`8%"P$!```&`P$```````````````$$!@<("0(#!0H0
M```&`0(#`P4$$!((!`4%``$"`P0%!@<`$2$2"#$3"4%1(A0*D1475V%QT3*2
M(W.SU%65U1:6.!F!L4)2TC.3TS1TE+;6=Y<86!JAP7(DM+4V=O%#5"=B@E-$
M)29&QD<H$0`!`@0#!`4%"0T&!04!`0`!`@,`$00%(1(&,4%1!V$B$Q0(<8&1
M,@FAL<%"4B,551;PT7*R,Y.STY1U-C<8X6)S)'0E\8)#-!>2HE-C-=(F_]H`
M#`,!``(1`Q$`/P#/#N-J6K!8X4617@OE5DS<YS$[L$B$-N'*`[B83^774XX4
M2D([6FPY.9V1X3X6W>P<T*D`[`(AWRH[;@`_K?DZZN\*X".WNZ>)C7X6W7VF
M2_=5?V&H=X5P$.[IXF'PMNOM,E^ZJ_L-.\*X"'=T\3#X6W7VF2_=5?V&G>%<
M!#NZ>)A\+;K[3)?NJO[#3O"N`AW=/$P^%MU]IDOW57]AIWA7`0[NGB8?"VZ^
MTR7[JK^PT[PK@(=W3Q,/A;=?:9+]U5_8:=X5P$.[IXF'PMNOM,E^ZJ_L-.\*
MX"'=T\3#X6W7VF2_=5?V&G>%<!#NZ>)C<3+#HYTR#$H$`YR$YS*K<I>8P%W'
M@'GU-Q*Q3'JTZF9'IMKM.FXZKL;,>T3KV)51>OUV2;1-I'E>=\0[=)4RASF,
M!=AV``#7:VV%SGNCJ=<*)2WQ9`7Q4+&8`$,3PA@\Y9]_M^ANTUV]W3Q,=7>%
M<!&OYTZR?%+#?=]_]B:CW=/$P[PK@(?G3K)\4L-]WW_V)IW=/$P[PK@(?G3K
M)\4L-]WW_P!B:=W3Q,.\*X"'YTZR?%+#?=]_]B:=W3Q,.\*X"'YTZR?%+#?=
M]_\`8FG=T\3#O"N`A^=.LGQ2PWW??_8FG=T\3#O"N`A^=.LGQ2PWW??_`&)I
MW=/$P[PK@(?G3K)\4L-]WW_V)IW=/$P[PK@(?G3K)\4L-]WW_P!B:=W3Q,.\
M*X"'YTZR?%+#?=]_]B:=W3Q,.\*X"'YTZR?%+#?=]_\`8FG=T\3#O"N`A^=.
MLGQ2PWW??_8FG=T\3#O"N`A^=.LGQ2PWW??_`&)IW=/$P[PK@(?G3K)\4L-]
MWW_V)IW=/$P[PK@(?G3K)\4L-]WW_P!B:=W3Q,.\*X"'YTZR?%+#?=]_]B:=
MW3Q,.\*X"'YTZR?%+#?=]_\`8FG=T\3#O"N`A^=.LGQ2PWW??_8FG=T\3#O"
MN`A^=.LGQ2PWW??_`&)IW=/$P[PK@(K!@7Q`9O,F6*IC=WCJ-A$+&>1*I*-Y
M=TY4:^HQSE\7E1503*<5#(`7M[!'70\CLR`G&8/N"<<>\JSI3(2491:WXB7C
M$6;H>Z@T\*1.&8&^-5*+6[<69?V1_%N^^G%Y-)5H+1LU52*@W(Q*)3"/,83#
MOPVUDIRAY%6?F/IQ5[N-?4TSH<*0EM"%"0*AM49SPC&/G-X@KSRPU2BP4%OI
M:IE385G<<<2J92DRDD$?&BQ7_,C7W_##5?QVE?L+5W_Z-K:<1=JJ7^&W%FSX
MV;L#(V>CG_BN0_S(U]_PPU7\=I7[!T_HVMWUM5?FVXA_6U=OJ>C_`#KD/\R-
M??\`##5?QVE?L'3^C:W?6U5^;;A_6U=OJ>C_`#KD/\R-??\`##5?QVE?L'3^
MC:W?6U5^;;A_6U=OJ>C_`#KD/\R-??\`##5?QVE?L'3^C:W?6U5^;;A_6U=O
MJ>C_`#KD/\R-??\`##5?QVE?L'3^C:W?6U5^;;A_6U=OJ>C_`#KD/\R-??\`
M##5?QVE?L'3^C:W?6U5^;;A_6U=OJ>C_`#KD/\R-??\`##5?QVE?L'3^C:W?
M6U5^;;A_6U=OJ>C_`#KD/\R-??\`##5?QVE?L'3^C:W?6U5^;;A_6U=OJ>C_
M`#KD/\R-??\`##5?QVE?L'3^C:W?6U5^;;A_6U=OJ>C_`#KD/\R-??\`##5?
MQVE?L'3^C:W?6U5^;;A_6U=OJ>C_`#KD24^&7XJECZ_,FY(H$UB.'QVC1*(Q
MN",C&S[R74D%7=@;0IF2B+ENB1),A''>`8!$1$-M68YU\BJ3E19:.ZT]:]4K
MJJHM%*TI2``V5S&7?A*+Y<B^?E=S=O5;:ZJA8I6Z6E#H4A:U%1+B4$$*P`DJ
M<XF>UC?&3<-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(
M0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA%
M',NB(-X(P"("#EWL(?4T=2U1NB9I]_FBAY>)2B(B(\I?*/F#Y.I>)F-=@^3[
MH_-TA#8/D^Z/S=(0V#Y/NC\W2$-@^3[H_-TA#8/D^Z/S=(0V#Y/NC\W2$-@^
M3[H_-TA#8/D^Z/S=(0V#Y/NC\W2$<J10%9$!W$.^2X"(C_YA?DZ]&/-BW?Q2
MA$M`Q,!1$H&N<QOL.V__`.$)YM3-/O\`-$M4;O/\$0N@&W`!$`^08P?Z]3$2
MT./G-]$;YND(<?.;Z(WS=(0X^<WT1OFZ0AQ\YOHC?-TA#CYS?1&^;I"''SF^
MB-\W2$./G-]$;YND(<?.;Z(WS=(0X^<WT1OFZ0AQ\YOHC?-TA#CYS?1&^;I"
M''SF^B-\W2$./G-]$;YND(<?.;Z(WS=(0X^<WT1OFZ0AQ\YOHC?-TA#CYS?1
M&^;I"''SF^B-\W2$./G-]$;YND(NRZ'/RHL8]H_3YT.(B([#`2.^V^^VNEU(
M)Q^2KWHY($U@\%"(R_']W'KR1Y1V'X%*`7<!V'8SRP[AN/'8=;#O"PVD<OE$
M_P#SK]&=R-9WC`>4CF2B1P%.G\1N(1-B=G.?W3:RC`:EZZHQ+[5P[A]WGAL3
M]>?W3:C\U\M41SN_)$-B?KS^Z;40&SL6K[O-`N.#:D1IL3]>?W3:A)KY:HAV
MKG`?=YX;$_7G]TVDFOEJAVKG`?=YX;$_7G]TVDFOEJAVKG`?=YX;$_7G]TVD
MFOEJAVKG`?=YX;$_7G]TVDFOEJAVKG`?=YX;$_7G]TVDFOEJAVKG`?=YX;$_
M7G]TVDFOEJAVKG`?=YX;$_7G]TVDFOEJAVKG`?=YXR+O9O\`E_O'=0NQC#_[
M)0_`1$?_`-]QOGUB)XP,GV0M.51/^Y*V_P""N,UO!0I2M87<D`?[:/T[<9@^
MM?L;'X:0AI"-@[\V^X@&W9L&W;Q'S]FHX2Z8XY59\T^I+9'A,C9*H^)J=8,B
M9(ML%2*-5(]>5L=GL;]",B(I@@&QUG3MR)2E,)Q`I"%`RBJ@@0A1,(!KJJ*B
MGI*=534J"64"9)V"/5L-@U!JF],:>TU2/5MZJEA+3+22I:SO.`P`VJ)P`Q)`
M!,8OO4?[2N"UU^#3H9P(\R_*/9<L!!72_MIM)"UR;@Y6C0E,QG5Q2M<J5R].
M`("Z=-55BCOW!0XA:^Y<S&E.=UT^QWATJRA9GEGY!,GW!&SKES[-BNIK*=6<
M_;\FQVYICMW::E#:G&V1(J6\^ZK(V4SD0A+F)PGM%R&*<@>T<7Y@QODIC7HV
MH46[`CI+&^40E8*=5:J;J%(Z2JDM9I.&6[LP%[IT[37(.P'(4=]3])4\QZBG
M#Y;MR<TB$JS@RX&1P/E\L6\U58O9QV.J7:*"ZZYKW6CE54TIIW&B?E!3K#0*
M1O"6UYA@"DD$2'X(ZR\PA;*]A[K:P`\Z:<JV5[[U4FXU^>;7_I^RS*B4QDXB
MI9!9!WM6MKLA!,W@YPC=TZ`!!LHN<!(%5T-RK$)2S?6$TU6M02DA>="U'XJ2
M-A/3&,^NN5NE!;W-5\FK^UJ+238*GF76C372D3CUWJ51(6PGXS[9(E,E"1$C
MA#@;AS;B';V!V\0'Y6O;E%B`5)5V:C-<<NH1VPTA#2$-(0TA#2$-(0TA#2$-
M(0TA'"HIR`(CORAVB&V_8`\-<DIS]4;8!*RL`2RRF9[HH=GKJ0PITRTAUD?.
MF3*OC6GM=R$D+$^*BXDW>QCDCH.,0!64G914I!`C9HBJJ<1#@`<=2M;745MI
ME5%:XE"$\2!%7Z#T!K7F=?6].Z!MU3=+LX?4805!"<>NM9DA`F",RE`88=./
M?E[VF?%#6P.:OTP=-64\Y/"%/ZI,V!PG36;WE$0]895>'B[;;5V8`&X"LDU.
M)!#<I1W`+<UG,R@02BUL/5;@)GE3(`#8?/\`!&PG37LSM9M4*;KS:U+:=,M+
M2,K4TOJQVYRIQD!0X)SCIBWNC^U%W*+MYXC.W2"TAH)-TFC)$HMVE&MR@4SC
MZ9UX.YPK=K(.4D]S=R=5D)@#;F`=M_-3S6[%:17T*FT%0!ZQ)`.^1"??BO[[
M[+)NKL)K=`:U8KKB6R4=K3H2RXK<D.MO.Y2K9(I)WQE!],O5!AOJWQ17,T8/
MMZ-LI%C!=`BAT192\-,,Q*$G7K'$J[.H6>BU%`*LW4#YT2G(8Y#E.:ZMNN-%
M=J)-;1*2IM0W;1T&-7_,GEQK+E-K*IT3KNC717Q@`@3S-NHV!UI4NLE6T&?0
M0%`@7$;[]FIN*(AI"&D(:0AI"&D(:0AI"&D(T'L'R<!XAY.'R0'2'DQ,=11P
MFW3.LX6*DDD111114Y"))ID+S&.HH8"%(0A2B(F$0*'E'7)90D9E$!,0;"G'
M.R9"G'%'``3.;<E(`Q]V.-C),I%JW?1[QM(,7B";IF]9KHNFCILML*2[9R@8
MZ*[=4IMR'*(E,'$!$-<&YJ!/3'8^V[3DH?0I#Z592E0((/`@X@C?..^'9J,<
M#&ND(Z;QXW9HK.'+A%JV;H*N7#EPJFBW;H($,HLLNLJ)4TDD4BB8QC&`I2@(
MCPT*D(&=P@)B*&WGW$L,I4IQ9DD)Q45'`)2G&9)V"(;\;>,S@K-?7W7>B?#C
M)>^0\E&75M)9M8R*"=65O%5BW4R2O5*.!HHM8X86D:Z37E.^10%<A00*J3=3
M5+L:QM57?DV*F3F<*5',#U>J,1&7&HO!SS(T3X?W>?&MUMT(2_3I:M\CVRF7
MW`V''23-M?6!R`;-LC,"9(#*=P8W,83[`(#Z&X#L'#LY?]&JI*#@B?6XQB+U
M2)9I)'QN/3\$4ER]_!H/^,NOK:.I6HW1-4^_S11`GSA?]DOZ0:EXF8W:0AI"
M&D(:0AI"&D(:0AI"&D(Y4?VY'ZLE]<+KT8\V+=?%+_Z!Q+_WG,?\D3U,T^_S
M?#$M4;O/\$0O:F(EH:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0A
MI"&D(:0B[+H<_*BQC]7GOYOR.I2I_*(\BO>$13ZZ?PA[\1E^/Y^7FC_4OC__
M`(RP:V)^%;^7BO\`'5^.Y&LKQ@_S'1_IT_B-Q"$(;F`-P#<0#<=]@^2.V_`/
M+K)P;(Q29VQKL4#`4Q@\P[;^B?TOI>^P`900+P*7<==K2F$JD^93V1-.(=4V
M%-`F6V!B[`!@[!#<!WWW#?Y8["'F[0U-NMI83VC6(,2J5+<7D7MC9J0C@<#*
M&D(:0AI"&D(:0AI"&D(R+O9O?RC^H;^I&'_GW&:Q'\7O\)6K]XJ_0KC-?P3_
M`,7W?]VC],W&85K`&-C\-(0TA'5=+)H$456630223,JHHL<$TDTTP,9510YA
M`I4TR`(F$>`!Q'4)J2<RI=C+'C#LPM2?6*BJ0`WD[!+>3'YYOC0^)S9NM7-L
MQBK'5@>-.EW$D\]BZM&LG2J;+)]IC556<EDJPIIF`C]F#E-5*#14YB-VA?6`
M`%5Q$MAM;ZO1<JURUMJ_VYKJ]6<UJ($\QW@$8"0EC'T,>![PL4_)W1U-KK5;
M"5\S;RPE84<I%)2N`J0VT"DY'<N93RLQS$)DE,L9U?`.\-6M82P_`=9F7JVT
M=YLRW$#)XS1F&B2I\88LD"&-'2+!-T008V>\,B^MKN?050CU4D0$O,MS5CH#
M2:K9;4W2JZE6Y,R$@`V9$8&?6/1NW1@/[0+Q/5_,'6[W*?1SSJ]#61X-/Y%R
M565>*%=9,LZ6U$I[.8!6"HCJIBYW./B\6L;-:*#T%='N7NMQ_2'SV&L^4:DP
MF8S"<5/QRZC:1AXBUL827/=7<>Y(*:XLS(MP4`2D5/L(A[%=J]2:KNUEH7ZX
M)]92`$I29;)J`GCO`E%JM%>$RRLV>DOO//65GT335:,U/2.S>KU`IS9GZ="@
M:9"D&:2YF),@0DG"/V"]H0;HWY[@CQ$>B>>Q$S=OV*%A%D$S)2%6%-XFXCY>
M9QW<X:+FW+%DZ0(X2=,'9W"9DN\;IG.0-4[3<P5LUI9O5M73I!D%*QD9[3,[
MMLTC#=%_:_V=E57Z5&MN0.M:+4%0\RK(@H#?:H*#F:0\TM6+@.7LG0`J9"B!
M.,H7&V0Z7E.C5C(^-[/#W.CW&':3E7L\&Y(]BYB(>)\S9VW7*8!YQ#<JA#`5
M1-0IBG*4P"`7-9JVZAE%4V0:58!F#Q^"-9NHM/WO3E^J;+?Z9RCOE,ZIIUEP
M24VM)D2I.!*=XE@1(@D$&*CZ[H\F&D(:0AI"&D(:0AI"&D(:0AI"&D(LTZY^
MLO''0KT_V_.^23>^",<5&&I=0:.$D)B^7F334+"56,,J;9,S@R1UW3@0$K1D
MBJL8!Y0`?*OM[H-/6Q5RK3)`,O*H^J//%T^2_)_57/3F+1\OM*-S=J!F>=/J
M,,A7SCBSN`21(;U$;ID836`L6]5OCR]94S:\Q7*5AL9TI5O+7J:B_6/P4Q%2
M'CY8T1CK&$.L`L"6JPI-S)-U5"G5."2CQX*H)@0UDK;0W+75X4_6.+%K2J2@
MDR'R@D`S$R")S'3&['F1JSE3[/CDW3VC1E&R[K2H26Z9"A\^_42DY5ON(R++
M")`Y)A)P2G'&,XOICZ.^F_I*HL?0\#8MKE+CV3=))]-%8-W]SL;HA`*K*6JW
M/45)J=DG0ASG.JKW91-LF0A=BA?2WVFBL[0IZ)IM#>4"8&*I?*.^-(7,GFYS
M&YLWUV_:ZN]56U+RLZ49REEL'8&F0<C8`ZN`S&4U$G&([_&F\/+%?5%TJ9/R
MG$4V(C.H+#%0F;]2KM%1S9I.3\75VCB8GJ+/NT2)&EXF9B45Q;^L=X9H[*FH
MF)0[PIZ?U=8:*YVE]XMH%6VV5)5+>!OX\(R`\&7B%U/R@YIVNPU-8^]H&[UB
M::II7%%:$J?(0V\T">HXA9$U#:A2Y@G*1"Q[+EDZT,LZ]1V&`?KJTB?QE!Y+
M&*%41;,;57[`RKA)1!$P"5-:1A)\$%A+L)P;I;[\@;6^Y0UKB555O<45(*0M
M,]V,C+H(C.KVJNC+*K36G];M(:1>V:PT:E2FM;3C2GD@JV]0I!_YC&:V`;<`
MU>^-)T:Z0AI"&D(:0AI"&D(:0AI"&D0.R(0_:";WD+'WAMWQ_CRQ3%9=6+(&
M/*;:I"#<K,GSBDV*3=(3D0+QL8CANRF546[9QR&*)T%#IB.QQU1G,-52C2U2
MY2$I<2D8C:)D`^_&:'@%T]IO4WB5M5!J2G:J644U0[3MN#,V:AE`6V5)W@)"
MU2PQ`.Z+J/"AMBEW\.CH[G%5N^4#!M2@EC"?O#D7JR;FK+)F,)C"`D&'*``/
M$`[=>WIVN-?8**N5^5=:1/A@D#X,8M3XI;"UI?Q%ZNLM(V&Z!F[%;:9;`ZGM
M=VZ:\.`PB1,`V``^1KV(L-'S9*2;1;1Z_>NFC)A'M'#U\[>N$FK5DS:HG<.7
M;MRNHFBW;-T$Q.H<XE*0@"81``U&;:4E3AD!'-#3SY#%,A2ZM:@EM(!45J)D
M$I2,22<!+>8P??&8\:N5Z@Y"Q=*_2C9E8S!+)5W#9+R?#*KLW^8W;<YT7=>K
MKTID7+'&B*Q!*=8HD4F1#<1!KL56R6L=<N/J7:[;_P!H)AQP3S3X),]DMN&V
M-W/@F\#U#I9FFYM<Y*9"M4*0':.A=25(HTRP6^G#-4*,E)Q`;1@053E:E[/E
M0I&Y>)CC"7:(+G88WHF2[Q+.42?2&C8*LXJK$JP[``%=R5D13*`=HCP[->3R
MZI4NZE;J&IJ;0VO,3B1F$ACY8O-[2*_4=G\--7:ZET&KKZ^C2TF8!7V;J7%A
M"0!ZJ$SWR$?H;E+])4#?APX\H]FQ>(%WXZR`+J^S#OQ_[?O1\['S"F^S`/9)
MP\N_#TQ2;+W\&@_XRZ^MHZZ*C=$]3[_-%$"?.%_V2_I!J7B9C=I"&D(:0AI"
M&D(:0AI"&D(:0CE1_;D?JR7UPNO1CS8MU\4O_H'$O_><Q_R1/4S3[_-\,2U1
MN\_P1"]J8B6AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0A
MI"+LNAS\J+&/U>>_F_(ZE*G\HCR*]X1%/KI_"'OQ&7X_GY>:/]2^/_\`C+!K
M8GX5OY>*_P`=7X[D:RO&#_,='^G3^(W$(@#RF`P#MZ6PB'D*(;";Y0`/'63P
M3M\LO-&*+7K2.&$7WXRQ2HMTWQDO5(G%]URKGK*,YCJLQ5I;DE+%7*15(8#V
M69KA7B2$?5GK23EO77LP*NS1@V$VP["&K6:EOJD:L=H7RXFRVYEMS,UZ[CKR
MUMI0H$R*>JD!(VE1G/"+SZ;TPS5:4:N%.M*KW6N.H[)P2;2TPVEU:P0"J>52
MMN'5'3%'B],.19*QXTKU=E:+<$<K/['"U*TUJX,)&I#+TYF=]98V8GE4F:,0
MM#LR%6557(1(Z*A52&,0=]5"SS"LB+;4NUZ:A`I,H4D)!7-0)3A/&>4^<2BG
M1R[N=5<J=FB<:+=83V2B3E*@0%`F6P%0$44ME9_!*?>5\\]6[(HQ[HBLO4)4
MD[75W!D2JKH1\PBFF@^]4$W*<Y`Y-^P1U45CK%W9H/.H+:%"8&^1Q$P=\HI&
M\VQJV/*9;65J22#LV@R,I;I[(\R(;#MKT7$Y'"D>J(\C*,@5O,::XQQAI"&D
M(:0AI"&D(R+O9O?RC^H;^I&'_GW&:Q'\7O\`"5J_>*OT*XS7\$_\7W?]VC],
MW&85K`&-C\-(0TA$07CA=3DGTP]`.49:L2)HV\964885J3MNY%L_CUKTF]2L
M,RP.014]9BJDR?"0P!L110@[]FJ4UI<56S3SSR">T4,J?*K`GT1E;X*N6-)S
M4\0MGM=U3VECMP77/HD2%=AE[('@.U*9SP*9B,"GHBP$'4UU88`P%W2ZD7D/
M)-=BK`9!/G.WI[%R$U<%P#B!>ZJ\4Z*!C#L7??S!JP=BM(N%_I*1TYDK6%*,
MMN_9T?#'T!<_M>?^*>2.I=84H^>HK:ONZLTBEU[*TWEP(ZA("4[Y[H_3[O>)
MJ]?L:RV(U'<G6J=,0+"IO6]5=FB'Y*B@5LS?UR/?(;+Q;25@D3QZBJ`D73;K
M&[HY#@4P90KIT+833D$-H.$L`1*4O)*/ELM>H[E;K^G4Q[-ZZ)J#4)4ZG/\`
M/F:BXH'!2DK(6)S&;:"(]#3<?U/'57A:718.(J%/K48UAX&LUR,:Q,+$1K(@
M)-VC!BT*FD@FFD&WE,;B)A$1$==[2NQ9#3:4`@[A(;MT2%WNMXU!=7[W?*IZ
MKN]2O.X\ZHK<6J>Q142"@;`D)$A(`@`1!S[0%T;5G.G1O:,[1<`W'+_34V1N
ML78V;4@2\MCPSYJA>ZO(.DR`LYC&T<L,FB!A$&RS,3$Y044$U#<Q+6S76A=:
M!_F&$*6)88)!,NGR1FY[/[G!>N7O.RAT8NI=&F]1N&G6T%$(35*F&%(!S!M2
MED(*@)R(X"(S/9HNLJ;1N60>B.WS"KRMS$+*Y9P\@[5,<L%,Q2K%.^UR.,H<
MP)L)E@NG*$0*'*1PW<J``"J?5/<N+JYF78Z@YV\@6@D[#O3+T';&4'M.N3%K
M;IK?SUL3):NAJA1U^0#(IH@]D\N4NL2,FS$K&.$9F&KLQIVAI"&D(:0AI"&D
M(:0AI"&D(:0CKJJB0IQ$`Y0[!WXCQX^CMY!UQS#*3O$04<O_`*9^?AZ(P%_:
M*>KF0S;UEC@*'DS&QWTPQB,"=HV<G%F]R?9X]G,7:6<(@;D5>0K!1G%IB(`*
M0H.`*(=X;>P/,RZJN%R^BB)T3`!(GZRU)!GALE,8;\=D;\_9M<G:;2?*-?,J
MJ;R:BU%4*DX1UFZ!I:FTI3/'YS*IW-A-*P,9`QE"^"ETP1'39X?>%T@C4F=T
MS%#MLUY`>&0(5V\EKPT;O*^T75Y2+'0@J<5@U2(8=B"0X[;G-O=C1MK:M-@9
M:3(N.`.*,I3)`\NR4AT1JV\9_-&X\T_$'?*ZH<S6FV5"K?2(!S(0S2DHFG9B
MXX%N*V^L$SP$2Q@7N?G0$XG$-PWV`-@`/+OJJEJ4H3PPC%%*"V"&Q,J,S/9/
M?+AT#RXQ8#XH/436NF[H6ZB[[/OV3.0DL>6&@4IDZ6[M:>O%^C'=7K\0P2'E
M.X<">1.X4`H[D;MU#CZ)1'5/:BN-+1V*I?J%Y$EI21LF5$&0`)&TQ?KPU<O+
MGS+YY:;TW;FEK(N;-2X4I*@VS3+2ZM:Y8)!D$`DRFL1"_P"S+=),Q0<9Y3ZM
M+8Q<,E\QF8X^QH5TBHB=W0ZB^7>3]D0!0`%6/L%H*1!JH`;*$C3FW$#!JA^5
M]J>I:%=T>3+O'5`.T)3B#/I.Z,U?:=\X+3JC7=LY46%]+XL"7'JQ:532:A\(
M0AJ0PFRV@]:9)[24@08RIM77C5K#2$-(0TA#2$-(0TA#2$-(0'L'4"9`D;8>
M79$<OBRXG5S9X=?591F+4KR72Q;)W6"3[OO%BRV-WC"^-S-M@$Q5CDKYT]P]
M(2',`;[CKQM24AJ[!5-&<^Q4?0)R]R,@_"IJU>B/$5I2^9@EDW9%*J9E(5B%
M4TY_W>USRWY0,)Q9K[.OD9.[>&W5:^#LKA]B_*&2Z6[2,H!EFS5W*(76**8F
MXF31.TM'*F`_J2#MV:I[E]4E_2S`.VF4I$N,C[GK1>;VC6FZ>P>)BY5S!,KK
M04=89B0S$*:*1CB),@S_`+VR)V17.FF)A(!N7E_5;?/"`"(B8`*`%WW'CV:K
MS"<U8(E.<8)([3+*0S2V;Y\/O<8PK/'0\8%?*4Q:>B_ICLXML:1:[B!SADN!
M=@(9"F&IQ2>XZ@9-L<!+3(MP0R4FX1,(2;@HH%$6Y#BK977>K%5R%6BQK&9!
MDXL'=P'&6_&-U7@5\&+-FIJ7G5S:IB+LXWVMLHW$9@P#BV_4))!0MP=9M.4E
M(E.2B0(*>C3H9Z@^NG(!,>X+J*CQO'';GN=^FO6&%"H$8MLH$E9YLB"Q`6%`
MPBV8-RJR#H2[)I<NYBT'8K'<KR^+?2B5*9%QTC">STRZ??C/[GEXAN6/(72:
M[]KNI)N"T28HFB#55"ALRM8'LT["LE,@)2.$9ZOAC^%5BCPY:U9W,/:)3).8
MLAQD.ROV19-BWBV96,:=5TE6Z?!I&74AJ\G(K&6.*RZ[EV<J9U3!R$(3(#3F
MF;?IQI35*DJJ%)`4X1(G$F0&,ACQ)Z8^?WQ-^*S6?B5O-.;HTS;]+T"UKI*-
M!SJ1G`27'5D)S+*0```D)F=NV)7>7T1#?]';_5V:J275RQBY(;/BQ1W+W\&@
M_P",NOK:.I>HW1-4^_S11`GSA?\`9+^D&I>)F.9-%943@DDJH*9@*<$TSG$A
MA`1`I^4!Y3"`;[#Y-<PVXK%*5$=`)CCF3U<1UO5Z?)Q\T<OJ3S_TCG]P5_8:
M%IP;4J]!B,Q.4Q,?!M]&^-/5'7_IG';M^TJ=HAN`?.]HAK@`29#$QQ*T)]90
M'6`Q(VD3`\I&(&V6.R-?4GG#_='/$=@^D*\1'L`/1[1UR#;AV)5Z#$0I)!((
M(&W'9/`>DX"-/5'6PF]6<<H;@)NY4V`0[0$>78-M^.H]D[L*5>@QSD<.DD#I
M(VCRC>-L!:.@[6S@/EHJ!^F70M.C$I4/,8@>J0%8$@D=,C(R\AP/3`6CL!$!
M:N`$.T!14`0[.T.7?RA[NN78/_(7_P"D_>B(22$D#!9DG^\=LD\<,<(>J.O_
M`$SCR?\`DJ>4=@_4^4=<>R=G+*J?D,<%+0A*G%D!"20HD@!)3ZP)V`I^,#LW
MQP;"'`0$!\PAJ!0L'*0<W"4<E_-@*7U4JV$X`SQ$N,QB)1R(_MR/U9+ZX74_
M'FQ;KXI?_0.)?^\YC_DB>IFGW^;X8EJC=Y_@B%[4Q$M&TZA$]N\.1/<!,'.8
M";@'$1#F$-P`-(0*<AR\Y3E,7B',4P"7<!V$-P$0X".D(W></*`B`_($.`@/
MF$-(0TA#2$-(1IN'G#W=(1KN`=H[:0CB,N@4PE,LD4P;;E,H0#!S<"[@([AN
M/9I"-Y3%.`"0Q3`/-L)1`P#RB`&V$-_G1'CYM(1N$0#M$`^6.A(&V$:E*8_,
M)"F,!""J<2@)N1(#`05#[`/*F!S``F'@`CMJ&9/$0C0>';PV[=^&HPAN`]@[
MZ0C3</.'NZ0C72$-P'L'?2$-(0TA%V70Y^5%C'ZO/?S?D=2E3^41Y%>\(BGU
MT_A#WXC+\?S\O-'^I?'_`/QE@UL3\*W\O%?XZOQW(UE>,'^8Z/\`3I_$;B$,
MH%$1YA$H<>)=N8-^`<G,`E$^_8`]HZRJ2V9*)F!D)\\8K+2E&7+B<P]'FB_9
MCEVHXB>8&ICMU^%,#5<"9$JF0G=)>,U)"#MG4(TF%+`ZK<BOR,UINGPSR-05
M$XB"ADSH`)=A'5B&]/W>_4U?7IST]P76,%)4E2<R:=U#B0<TMIS9<<9\8O0U
MJ.CL%?1V]*4OTHI'@<I"LO;-*;7LG\7;T;8^#%9_H-)BH6G4J-LSR!HN*<T0
ME6L$^WCV4O/Y9S*U;0DU>'T4Q45;0</$5E(&K)L"BBZ14=C&'F#7KU7+^XUO
M;5M8_*X5S[3@`!D`S/JDSW*7CB)3(B7^WM!0H:9M[$[72,N-(Q!4''<O6$A/
M:F8DGSQ9,1,4TTBE+L"9"D('*'H%`@$Y0V``#T0`.';J[5-3(HVD(0052"<)
M;0,1Y<)RX1:*J??JG%..`R42K?LF<?3AY8"`^8=QV\@\==:U)4I,B"I4Y`';
M+AQ\T=);="25)5D2<3(R!X'A&FPB.P`(CV;``[[^;7`X*"#ZYV#>?((XA"BD
MJ`)2-IW#RQKR&W$.4VX=H;#N'R^'#4)@J*01F3M&\>7A''8`3L.SI\D:"4P=
MI1#R<0$..V^WN:9AQ$1"2H%202D;>B>&,-A'L`1_0'7,(6H9D@E/&40/5Q.`
M,::XR,(UV$.T!#]#2(3$9%OLWOY1_4-_4C#_`,^XS6(_B]_A*U?O%7Z%<9L>
M"?\`B^[_`+M'Z9N,PK6`,;'X:0AI",1+VJ*^+>]G1[BU)4Q6[F2RI?Y!'CR*
M+L6=6K<,J(`8`$$"2;[M#@)PV\NK2<U:AU-+24J20VMTD],A_;&W;V4VG*5^
M]:MU2Z@&K8IZ.F;5O2'5O*<\RLJ.GJQ'+[.%1$+5XBZ5C<)E4)C3"62K4U$^
MP@22DU8&DMS=@^F#:T+F*/DY1\NVO#Y:L(J;SVZABPTLX\"4@2Z1YL(R3]IO
M>'K5X>V+72N%%-77VE:<`.*D(14.*2>C.ALCR8QG_(%,!C&$`V,```[^D(!V
M<P;!Q#CJ_*U9B`-@'NF/GU"LV&621L\N_P!X2CG,&Y1`-N/G[-O+V?(U`8&<
M05FEU/6F(H]U`TQO?\#YIHKM!)PVN&)\AUA5!0!.14LW49>-*4Y>4W,&[D/(
M/9J7KF45=&[3+`(<;4G'9B"(JO1%[J]-:VM&HZ!9164%TIJE!&T+:>0L>::8
M_-Y\**]/L3>([TB3`.56X+YC@*+,KIJ<B2L==DW%&DD5@-R[(&),`<X<>)`\
MH;#C?HZL52:HIGES*%NEO#;UYI$_(<8^D_Q=Z8I-3>&'5-LJ1G<9LO?$J&Y=
M(@5"98;R@`\1OC].8#AY=P\G'8.(>3MUDO@3(&9CYA<P&W`#></?Q]R'.';Y
M//V!_IVU!1*=Q)Z(BDY_5G*-`4*([`([@.P\!X"'G\WZ.H9CO!`Z8@E:%SR$
M'+MX^B-X"`]FH@@[(B#,3C0QP+MN`B([[``;]GZ6HS`VD"(*4$C82>@?=[L:
M=X7Y(<=N.W;MOL`;[CH3(`[C$9I$ID3/3&G>%Y@*.X";YW?;CPW\^X<-<5*R
MJ"<23[GEB`4"HI.!'$C'R8QR:Y1RC9SAOML/9O\`('Y7'4"0D3491Q"@?)YO
M^/N1J)RAY?D[>7W-)C?A#.GCC[OHVQ\&PS3.NP,U9'YB)1T%$2DV_6.;E!-E
M$LEW[DYA'@!01;B(COP#7%9#"7'EXH")R'0,8F[;3FXW!B@2/G7WDMI/`K4$
M"8\\?DZ95NLQFS,61<A2KI9[-Y6R1:K.[=*B4SA5U<[,]>@8P%X"=,'Y2@4/
MUH``=FL4JJJ[W<W*AT%074D2&T#-),_()"/K0TMIQGE]RXH=.T>3LK3844XR
MD)2KL&,JEC,4B:LL^,]L?JJ4$8+&N)*+'34A&5R$JM%J4.9[+/&L-&,V\16X
MUB0JCF16;(-RIIM=A`PEVV'65;0::I6PF26DMCA(81\HMU7<M1ZFK'F6W:BO
MJ:UY<D)+BG%..J7@$9B5'-NW[(B]ZO?'(Z%.F5G(0D#?R]0.4D%%V##'N&7+
M6P-QE@Y2-VT[>B'-4(EJHL(%/W#EX\+V%;G$0`:8N^M+%:!)+P?KC/(VU):B
M>D;!YSQC*#E%X).>W,]]JNK+:K3VEBDJ76W.=,E*!ZRD-*&=2I3*<X0@_*VR
MBRQYTF=<7C/9=IV?.O2*DL`]&]3=A.8YP`S-(P<U;V3KNCF3914B5.>;%FFA
M`2?V.43;NU6^Z<<W224YBTQ2VB\:TJ1<=1,KI[6F92S@"2#U21/9*>)QW2C)
M:_\`-WD;X+-(5G+WPZOMZBYQ7!LHK;P4A;;),TN)SF10H3S-MLA;9VK=!D#D
MF0.8^F'%UYH/2E"9&Q93\A(UQ&/H.#(ZP0;&R-:[7XSF:L8VK(+@[:H-(EN)
MTTSD(=1(ACE`P`8=7&IJJUTP1:Z=QH.@22B8"L!N2<<.B-<%7I/F+J*V5G,R
MHMUSK+&'%KJKB67"T5N.#,5O$920M4C(R!(V3E%RI50,&_*8.&X[@'#S@.PC
MQ#4X2$K[/?*?1%$$@>B<:@J4?/Y^SA[O8&N0QV$1RE).<D!/3A[FV->\+MOV
MAMON'E^5\G4#U?6PC@%I4G,#U3O^['W(V@L0?.';VAV[>7R\-<"XD&6TQR^+
MG^*.,Q[\HU[P-]MAX^7AM[N^N:>LG,(XE:0H)^5OW0%4I1`-A'?S;<..V^V_
M,(?*`=0,P92/P1Q[09PV/6/D'GQ(P\D;BG*??;]2(@/#RAI,3D(BA:5SR[C+
MT1J([>3?Y6W^L0U&.<;`4#CN4Q=O/MQ^5L(ZX(6')@`@CC'#-M*A+RD??C05
M2[\NPB8?)PVW';M$!V#MUVY"1,[(CF&=*"#UA/89>G9'P;#76%EAI:O2J15X
MN=BI6$D4!X]]'S+%6/?)#S%$/IC=<Q?E#HHA;:VEXH4F7OQ,4=354-:U<*19
M;JV*A#S2AM2M'JGR@XB6^,5+V>.S.L%]1WB`="]@[YL^I5U7N%>;.A!$Q@H-
MGDL:611!)4Q5%#.8US#*F'81%,H&#AN.K5<NGS37*OL-0H=HETJ"=P$R/-N\
MN$;2/:%4%-KGEUH+GQ:DA=LK+?W9ZH.!4IRG2]3SE/JI+52DDF86H``YIBJ/
MCS>*TK@BN2W1UT]615OF.\0P)9>N$(N/K6,*7,MMR5J-=I*;M;Q;V"FZ@EV5
MCHP_>>BJND)>WF+JQ5KIOHJ@)55NSS*3*38V=8SF"=FPRBG_``"^$M/,ZYM\
MY.85*HZ&H7PFD94#.NJ4&85D(D6&5"<R9J4)92!&.KX8WA=95\1#(9R)*NZ-
M@.HR+9/)>5UFASFW[Q-8:=12ND3-IFXO6_'<1%O'I&[UQZ1DTE+<Z2TE4W]P
M+!RV[-\XO&:C/%*<,9;#PC9/XI/%AIOPY:850TZ&:_F/5-9:6E21)I*1)M^H
M3/J-@2*`)D^K(&<OT*.G+IJP]TKXN@\/8.ID92J3`$`2M69.]D)N243)Z[8+
M++'3!Y.6"34)SN'*XF.8WHARD`I0R+H*.BME*FAH6PEIL`;,=FT\3TQ\\','
MF-K+F?JRJUCK>M>K[[4JF5.&26TG$-M($TH;3N`WXF9),5](3E$>`=G;ON(\
M=]AX!P#R<=31D3F^-%#I0E`PGF.V?WXY-0CE%&\O?P:#_C+KZVCJ6J-T3-/O
M\T40)Q(4/_A+^D&I>)F(V^IR?QG'=5^+X?/.2,FX\P^ZP?;WZAJ#-7F(2?W5
MM;8]M%^N)T=!V=P[".,KR\P;\GDV[*HMN;L3V<L\L)X#IQ\DXPCYY5UO3SIM
MEKU/7W2VZ53;%.?Y&MJ&T!T=Y)!+2VY8)3[D7&XCZ6ND3.M(5R/BS,_4+:*:
MB\E(]273S+DZ/%-W""`2J!F,H=F_!5F8=C%%,!`>`;ZBY6U=*HMH;:7VAQF)
MC#9(D=/GBHM,\L.6>MK,[?=.7W5+]L)*5K%YKYI4`<^Q\R)QF,)2BPO+CWI'
MF/@YK'35U`]1-GNUFS9C.I3#$UVS:LS<4J5MJ4-<.YD9./;0Z)"-S'W<`L`$
MY=P'7KV\.-?.O,4^)&Q(\YQ3NBP^N*/0YJ+;:>7FH-3OW5^[(#@<NE:X`&T.
MM*,UOJD00!%X^:\(=$G3S(0L3ES-W4M7']G8R#^'18Y*S-8"N63!4K=ZOWM=
M0EDVIDCJAL50Y#B'$H#QUYS#[RSF0&4B>Q4O_P"8O!J;ESROT$IJVZEONL#5
M5"4R*+M<""0K,"<KX`,Q%.>C?IQQ?U$TS,-V<93Z@)N!K^;<@UC'CU+,60X?
MUJBPJ;->L&?1[IVV=>M&;N!$Y5TR*B/SP;Z['ZIQ+C:2AM6)V">\>2*8Y,Z`
MLNN]-WF_N7G5;C%'>+DU3_[O7H*0P\L`J`?,R9),R=T>HZ-NC^C9MP#5\B7O
M)74&ZL<G/9!CG:K+-=S9(*-Z[>;%7XPB3<C[E+R1\<B4=@W.8!,/;KA65R\$
M=BD8;QCOCVN3?*2W:OT2UJ'45WU0Y4H?JVY(O-?ZJ:MT#8\#L2(X<)=(E(R_
MEW.SUGDGJ`#"..9IKBREK(9LO(.+-?(%,7>29P\F$ESN8^*DG*$60A/1!=JI
MYM<GZE80)R[3>.'D]Z.O07*6DU=J^\UC=WU4G2E`X:>D_P!YN$B_+KK2>VE+
M*XD?#%5LV]"F+J/AC*]T@,A]0J<W4L<7.QQIW&<KZZ21DX:O/I&/54;+27=*
MI>L(E-L;<.&I5MS-4"<YSPQXQ[W,/DA9M*\N;Q=*:]:J+M-:ZI]1^E*YX*=0
MRI;JB%/RF5"9XXD[(]IT[24A,=/V#I:7>.I&5D\34)_)/WJZCEV]?.JXP6<N
MG+A4ZJJRRRIA,)C&$1$=>?4__H`_=NB_/*EL5?+JTW+O%34+73-J!J5K<)"4
ME,YN*49Q65']N1^K)?7"ZZ(KJ+=?%+_Z!Q+_`-YS'_)$]3-/O\WPQ+5&[S_!
M$+VIB):+IL.2H5+!.?+I&1%9=V6)L&*V$4^GZY#6).-3F)"1:/B-4IIHY*GZ
MTW0*(]N_FU`\(1VCOV>7\!96M-GK=1B;EB:3J$E%6^K5N.K:LM$6=\\CW\#/
MMXKU:/>&1*3OT#`@0Y0XB([\&P]$1BD3#"63W\,[L*56<)0#*JM;LK,OWL<P
MCQK<@5RJP<H.WCM%&0?.DFAS`U;BLYV#<2!J,0CL4?!F3LB0GX1UF`;F@U'Q
MHQG(S4Y!5IO*R!.3O&D.:P2,<,JJGWA0-W'.4HF`!$!X:0CQJ-(N#BY$QZC7
M)0]U4ES0):X*`$?A+%.8IFI^<Q4"`!"BIW@G[KN@Y^;EXZ0CU]]PED?&D4A.
MVZ)BVT0O(%B@?1EJJT^FA)'3,J5F[1A)A\Z:*B4@ANHF4H#P$=)SB,H[T)TZ
M9HFZVSMS6IL4(20C5IE@,E:JG$2SZ)1(HH,@U@I289S*K<Z:9C$'N`$Y2B)0
M$-)C9$(HFJ`F'D`.)1.`CN`E$2&$A@`Q1$!$#%'2$7@-[@^Q[TRXDFZS$4PL
MK8;_`)&8S4I.T^M6!Z]9Q`QZC)L+B98.C)E:]\<2[B.P;;:AM)!V1'='G,KH
MPMRPUBO,J=8KU6ML[;;C2+$2M,$8*(M!8`J+F/L24,W4"/;29O6#(K"@5-,1
M#8=AV#0;91"/'PG3CF.V5^,LD+4TU8Z9;+/H-![/UZ*F9UDD"G^]0T!)RC2:
MD4EA1,"0IH#WOZC?70_NB(CT/3ZU!.)ZD4'S,IEV?3_;C^KOFI!.T>-)^%0-
M]*<I]\U=HJ',','*8HAJ7CE%.:!B>_Y/2DUJ;")/&4*D@I*R\M+1-=A&(N!$
M&Z2\O/O8]D9RL!1$J1#G4V#<0`..I^<A'"/CV2@W6EVH*5:*^ZCK(NHP38,$
M3(R"<K[Z`48Y6)?1YW+"20?=X`)'24,4P\//J,(J!9.FS-59K\G:96J-4HR%
M9HR$RW:V6L2<U$,%#$(+V2@8V7=R[-NB8X=Z)T0%/?T@`=)C9"/.T+$.0LG-
M))]3H1N[CHE=NT?RTM-0E;AT'SHICH,"R=@?QS1P^43()^Y2,=0"!N(`''0F
M4(^%*T"Z0%T''LM!*%N!WK..;PT<Y9S"CIZ^`HM$&CF)7=LW(N"G`Q1(H)>7
MB(@&^D(]Q=,!97Q_!N+)9*T@2'8.6[*7<Q%@KUB-!.W1@(@A/-X*4D'$0910
M1)S+%*0#@)1-OPTA%'-(1=ET.?E18Q^KSW\WY'4I4_E$>17O"(I]=/X0]^(R
M_'\_+S1_J7Q__P`98-;$_"M_+Q7^.K\=R-97C!_F.C_3I_$;B$1,P%.`C\[N
M.^W'AL.X?HAPW\FLI6*ETE+;FQ7W?!&**TJQ*-H_LBX*L8.9SN!KUEY:^-H6
M=J]HKE:J^,%ZU:W<SDDTV8Q57U9GFK08-?U-4BG,@D=0P`D?GY1V`:`KM>-4
M>N&]*K8[6B[,N/.9P$LY22C,/6FHC`[!*+C6G1C]5I-W57:EJH"@VRC*2IW/
M)*P)R`RI4)[3C@)3BD:=5M*@MR)52U+B\*\69)HUFP&,\;LS%]<<-B!'B=<C
M,3;+"0![OM-L''53KONFD-IJ'JM!4RZN:2]L2\K,)XX3`$I[8\(6/49)I6J5
M:4%*%9NRVJ:$MLN),XZS.&L#XZ98VO3TH1599-%2,@96127<-R?3VZ1F;-;O
M%FY>*A`#<@<3``<==M7?+-:ZA0>JJ=*6E)=Q4G`*0$\?[THEJ73]TN%,IQJG
MJEKD4(D%$9@K,=_03(>6.%Y&2[!%DZD(F38-GP*$CW3Z*D&;9]W:@(G!BX<-
M4T7QRJ'`!!,QC%'@(`/#7:W=;+,FCJ*9:J5D%:@4_-YYI!PG*?FB4JK3>&0D
M+9JPBI69)(5\XI,B0!/K$8'88YG<)8(IRUCI2O3T5(N^Y68LY."E8]\]3<F^
MD*,VKMDBX=IK&$`(*93`8>`;CPU),:BH'V@\V]3.--+S%X*2<LC/:)REOQW1
M%=DNC2NQ[&H0ZXF7925-6[9,>]%W\#T73CSIUIO4!8;4YJA[OU`HX)C*/*4J
MRN)XC%-LF_L.0'#1HV/-&B*\T.)UDB-C<Q2[\P%XZMG4\Y;-3:E?L=J#-12L
M6]3[K\T24[VH2EN<C,D'Y6$AA%TO_%-<YHRDU#<G%4]QJ+BEA+'9R*6^S4I2
MY3&PI^3OVQ1++^)#8XRC?J'3)Y3,,%2YQ."^$&IU2P(0<BN=H@L`*M%X\RL.
MY156[D4G!BG,<O#M#>MM+ZWM]UM%OO.HC3T5?54J5]W)0#F5,;))$R<,!NBF
M]8:(>M.H*^R::6]7VFC=(+C:2`H).(,BHE(E/'9PG'8KO3EF.S8:R+GB+I;\
M<88MG8NN7&QN"J-EFLU+JID28LXPZ/K[X&0*\SQ4I`19E*/>G*(;:Z;ES!TE
M2ZII--.U:TW1TY^R1.62:3C)0`F%"0(F<9;#'"@Y>:DK]//ZW8IE?0%+U3FF
M9K`5,`$&>*#.44==PLVP9H23Z&EV<6^V"/E'D1(-(R1WW$#1TDX;),GY1*7F
M`45#@(<0U4_TW:JFJ?HZ6MI''1+(E*T%0V8$#&>V*9J+#<F:9JK?HZEME0)4
MI2%`8S(VC#"7"/EJ[>B`#OL4-^/#FX[_`.C4X^CLW@@8I[,$G=.9G'@H2.SS
M_&*B);Y81D4^S>_E']0W]2,/_/N,UB'XO?X2M7[Q5^A7&;'@G_B^[_NT?IFX
MS"M8`QL?AI"&D(POO:H(]R3+?2'+"D8&3C'N3(PKC8=O66MDK;M1$H\O+OW3
MH@CQWV$-6<YL&0HE'U0M7P1N9]E#4!NW:R:WE^W>:8J2/Q3Z);2(HG[,2^9I
M=:&:V*@E%X^Z=))=H&Q.;NF60Z69UL8P\X`)7!-^4!#@&_DU)<JS_NCW!3*@
M.DS$5[[5)A9Y,6:H9433C436;=(K8J5)PZ4H6>B6,B1/.G2WW$1[!#<!]SR?
MH:O?L5E/`>Y_QC1253.5(ZDIS\L<HB!0W'L]WMX>37(`DR$<5*2A.96R/GRJ
MK8D9)&=&3*V*P>&<BJ'TH$`;J"L*FX;=V"8#OOY-<%X(/D,3%+F-2T$>NIQ(
M3Y9B4?EI=(2:SSKKZ<4&!#N3K]3N.2M4FX"8QC#DN,$G=$+Q^<\W#;6+]B!9
MU-0H=P4:Y.&W8LD[.B/JBYWJ0CPZZJ==Q:&CZT*/`BC7Y_1&;%XEOCAXDZ"[
MC(82J-'DLSY^81[&1F*Z9^K6*+2FTPR1DH<;193L7KU])OF#DBY&4>W5$J1B
MBJLB)@`;T:GUY1V%Y5&RV7:](F4[`/*=DL-QG&C3PP^!W7//^TMZNN593V?0
M+ZW$LO\`Y9][LEJ;7D;!!1E6DIFX$@RZLQC$AU.ZOJ*GT34#K+S5(P^+:=.X
M1I.8;HHJZ</(RM_A37XZ5/#QRBB17LNX/(2!6C)$B8N':QTR%()C`&JBI;NE
M-@3?JH!M*F`XH'XN8`RPG.7GC'?4W*B_TO.6X<FM&AVY7NEOU3;F590E;@8?
M6T'7!/*@94YUJ)R)`)G(3B$[,GCO=3N+8>#SI^;;R)$])-OE&S6H96R+:7]5
MG+-%/>$5+*1["KR\55S6!,HGCR.U%$G91*!%C&'5&7'7=\M]&BN<MQ^BE8AT
MK2%$'$')/,,-F8`]''-+0?@3Y9:SK'=$)YE4JN<+#2R_;V*<NL,.HVH[8'YT
M`2SJ;F$J)!V"<X_15UC8HZX<#5[/.*'4BE#2KIS#SM=G4FZ-CIEIC$VX2]9G
MDF:BS47;0RY%$UDCF2<MU4U2#RFV"M+->Z*^4":^D_)$R/0K:0?3&$_./E!K
M#D5KBIT'K="!<6`%MNH![-]E7J/(/!6((VI(*52(,>_ZBNHW$/2YBFQ9JS5<
M65,H=51(=Z_<D57>R+YT8$H^!@8Q$IG<U895Q]+;-$"F54-N/`A3&+.7*XTM
MGHEUU<9,"6.W$[!(8XQ3NA>7^K>9^KJ/1>B*0UFHJIPA")Y4)2)%:W%GJ(0E
M)F5+4D;@2<(QN&/M!75!U*Y$L=.Z$>A@N0(JK1,C9I&:R#9GBD@QJ,5WQG-A
MM#.$/$UFGM%DT1%,%YA83'^EE$YP$-6X1S`N=RJ'*>R6\OMM(SJ)4E,@)8XD
M<<!MZ(V.U/L_N7G+W3]!>^=^N6[565[J66V6&,X4^M02EMH&;KRL9$H;*!B2
MH)QCZ71K[2O5LIY(J^->J/#\9B1I;Y:/@XW*U'L;R<J$5)RBY&K(UJK\NT))
MPL,JZ7*0[YNZ>%;E'G53`A3'+,6'F*W<7^[7-CL%3EFG,`[`#O,S@)#;'1SQ
M]FI?]$:9>UARSO*KW3TE,:ARE?:0T^MM("E]BM*NS*D-DN%"I*4$E*05D).4
MLO*LV+)T^?/6[9DT;KO'3URLDBR;-$43.5G*[Q02-D&R#<@G.<QP(0@"83``
M:N6H%"0M4@DXXD1J\"7''>[-H<54E80$!)SJ6K`(0)34HG"29D';*,?;J/\`
M:)NF7&M]<XLZ>,>WWJON:4BK"ED**JE#49]+HJG;JQ]:ECL9N?MZY'!1*4S"
M-.W6V$4UCEXZH.OYAVFFJ54-&TY5U2#(AL&4_*H`$<2"8S_Y;^SQYH:KTVSK
M'7UTM6E-+O-AT*JU_/!J0Q4$G(TK^XZI*QO2(IO3O:.:-5;VRH/5WTC9QZ9'
M+ON559&01?3CN'9NS`1M*3%0FZW3K.$5\\)U6B;PVP>BF8>&I1OF32AU+-WI
MW*8J,@5"8/F$SY\!%1WOV<6H;M8G-1<F=7675;32`2TVM`<S'8GM4+<8098R
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ML\1CAJQ=#%2,XUAHUXR<MD7":(^_DA>7**?(H'**8D$OD`-7X'+JCJU)JKA7
M5CQ4@2`64)E+9(;>C891H6N/M!]36AE-)H#1FE;.\T5)[1;/>"2"0522AB2I
MB<SF/NQ*#TV>%GT)](Z\=*XGP%5OPM8E'U6]W@'&0;NFL!2E%9E,651^$2J.
MV_\`N*38`$>``&P:J&W:7T]:5=K2TJ$O8#.H9B9;)G''IPC&CF5XHN?'-8.,
M:OU!6&R+5,TE.KL*9,\,J4-Y>K+`)65YNF+/.O'Q(,K/[=.=&WAI4M]GKJN4
M*$;?;W7&324Q]T[M7(';'-8;&_.E4T[JCVD3=N`:QP\5P46`&^I._P!]N:B;
M7IILOW<[3@&T(EUB5*(2%8B0G/?%U^1'AVT<W0-<U?$G<4V#E>E:54U.Y/OM
MS5M3D80%/]UPZSG9C,2D#JDF,._`JV8<1^*!AHF:'MB0S;4.KVBQN27D])GF
M)UQ9AR%'PUB5D)DKE<98)`CM0H*D4,BLV5**?THQ0U9"W)K[9JYLW`J^E$OC
M-,SDI0(V@E)'6W&6,;J.8%)H'F%X4[M2:"2TG053I>H=HD,H"&2TPA2DJRD)
M<#@6WCG2D[=T?IA3UD@JE#2]ALLQ&5VOP,:]E9N<F7K>.B(F.8H'</)"1D':
MB31FS:I$$QU%#E(4`[=9.N*;:;%0\0E"!UB<)`"9]S&/F)M]'772M9M=L8=J
M;F^M#;;3:5*6XLY@$(2D$DJ,@)`XX1`-D#QT9G(]WM.-O#EZ1,G=:4E3$/6+
M'?6"<O7Z$FB*RR!',4BRA)6:?LG2B!O55'?O=ZX!1%`JA?2"AJC7!K'E,:5I
M5U[B#UBF24C_`)E%(/FG&>ED\#M/IFQ46J/$=JRW:'I+BA*F*1T]K6J"R`DJ
M0"$H!GCF]3X\A..GX=WCR1/5CG=KTP9ZPT&!LN3SZ6AJ@XC)Y],UN7M<`FX4
ME*3.LYJ+C9FK6@",7`()F]92661,B)DU1*!I?3VOC=+@+7<*?L*TJ*0F<^L)
MDB?'#?(;H[_$?X$;CRAT$.:&@KTUJ+1#;2'7E*2$.-M.*2E#J2V5(6B:A/),
M@&<I`F+]/$0\3S"/AST^O2.1F,[=,AWYO)GQYC*LD21D9U.).W2D9>7FGI1C
MJ]7HU=VDFJN<%ES'4`J*"I@,`5+J34M%IY">U034+!*4C:9"9QV`=)V[!%BO
M#MX7>8/B(O%12Z;534FGZ%UM-57/+*DL]H"I*$MR"W%E*21D20,,Q$\>SX9G
M7B_Z].ER2ZA[A3X/%:L5D&\U:0BF,TXDH2.A:HC'OV\JYFY1!B/HQL@!G*IT
MTDBF3,;E*7@'7I;4*K];/I1]L-()7A.<@DRF?*,91T>)GD53\B>:YY86VM?N
MR11TSJ72V$+4X^GU4H23\?!"<5E)$Q$?&<?&XS$6.O\`DSHOZ(KOU(]-6)I*
M4B+QU)R\C+UBB2;F"4%.<>4YE%P,I(R=<C!W%:4'F3(78YTBD$##Y%SUG7AI
M=38J)57;FQ-3F8(`E@<J5$*4!+:!OB_F@/!7HQYVWZ=YS:\I-/\`,N[(0JEM
M2&TO/(#H);%2H*RM.JPFV9$#?,$1?5X9?BDXC\1VFVIW789_CK)^/PBQO6+Y
M=^A,&9,)@54HNS5N>;M6(3];D7+=1+O#MFZS98O(JF7F(8_IZ:U12ZD9(;24
M5B$@K0=H!F`9[""1QGQBROB0\+^LO#?>V6+T^W<-,5Q7W6N;&5#N0!2D*03F
M0M*5).(DJ9RDR,2BK*%`H#N8-CE#T2F$1$=P*&P!QW$=5,4J5@DR,8R.%*AM
MP203N\W3/@,8A,ZL?&KQ'AO+@=-?39C2Z]9G4LH]<1BN/<4J;5V%F&B0'=Q4
MQ:FK":6=RD>0PF=-V#-T5F!3`X61,42ZH^X:SI:6XBTT+9JJX]4A&P&4\5'J
MC9CCAZ(S)Y4^#76&K]+#F7S$N5!I#EDM':)J:Z7;.M@@$M,J4DA1)!0'2V7$
MDJ;"A%B]=]H=R?C#J`88:ZYNC=]T[,G,G#M9E\QL$XK:J*PG3M_>ZQ3=7L$*
MS+8JT1%85%G+)=-04R&%)-0Q#)ZIZFYBUE/=S;;S1&G!($\P5($RG,$@@=!,
M9!7;V=^GM3\KU<Q.16LZ?4J4!>5"V$MI<4TDJ6VC*LJ;<.7*GM`$S(F1&4I'
MR;"58M)./=(/6#YJU>LWC<W>MW+5XBFX:N$%"ALHBNBH4Q3!P$!U=$2*0M.*
M2)@\1QC5\\P]3U+M'4)4BJ8<4VXE0D4K1@I)GO2<#TQA">)ED;(7AB>,C8NJ
MG&,,R??"_BY];XJ/EN]1K\M(W"F2&/+$D^[DBAG(0MRA&LRHD`?33D3*(E[S
M?5DM253VE=;N76C1_P!S3`$<3*2CYB$F-VWAFTO8?%7X,F>4NJJE*%V.\I:2
M4@]HRAMYIU@G#_K,K?;S8R$YRF)QF="'15G3Q5.J*?++3LT:#>3JU_ZC,UR0
MF>.HIG,2"KMR5FJXYD7MXM3@RB,8U^<3(4RHE!NW,&J6T[9+CJ^XK34%2*1+
MDW7.))GEXXQE+S\YW:$\(G*2FH+'2M)NYINZ6JW)($RRB27R!ZJ$'K..JDE<
MPE*BHB/T5L$8-QGT[8JIV',0U%C3*!1HXD7"0[/E.<P%-SNI*2=F$7$E-2KD
M3+NW*PF577.8QAX[:R+HZ*GM-.FBH6PEA`D)83XGSQ\XNKM;:FYAZEJ]7ZPJ
M':F_5KA6XM1F!,F2$"<DMH&"$C`#IF8K*4.4-M30`!*MYBF9J/K;8W:C"&D(
MHWE[^#0?\9=?6T=2U1NB9I]_FBB!/G"_[(?I!J7B9C8$>P7<)'=1[%X)#D,7
MUQLU6Y3%/S"8JKA)0Q-S<1*40`PAMKW&JLTJ@VB1'3/X(\&YTM'<EY+VQ3U+
MC8J9.+0DJ`[!4DS`&$\>.)BBWAVHE+TYYF[LO=__`.@NI`2E2*1("`2U29$N
M0A0Y2(@1,"AP_4Z[ZA2BZTI(&./1NC&KP_T*6=#7YOM$)`OUU4$HF,B>W<R)
MQ&R6S;@(J#X;T6R5Z+L'*+-&BBYHJS*\YFZ!S"H2]V02JBH*8<RI3$W`W`0'
MY.NFL4_DR))20!L]/NQ47A[M=K3RXM]4^PPNYJJJ]9<6@%8*:^I2F2I3]273
M%6<WK]2Z4A7R8%I>$+;%':O%)]QEN9L\4]9OB*D][RP_X/L'J;ALJD4W>"IR
MF`VVWFU*4;M*\KK)<3+?A\,XK'7M-KE]5.[I"FL=;3K6M2^_![,@)1-/9]G(
M2)`!GCB>B+<O#D2LKBD]2@79C"Q=G5ZJLN_A/'5I55:OM)54T8661A%%RD>'
MC"+"(("L4JO)MN`:]"K#:%-FBS).,YRVS$C%L/#HU=OL9?&;^AAFJ<U'<ENM
ML!0;"7*A:EA&::I;<I)F0!/&/:Y?4ANCKIE=4;!L:Y+:+3.+T7#D*NZ6>.U\
ME99L3Y9L^!RON8S*$>RSJ16W]%)NV-Y`TRU53B5'.,-WH^&*JU=4VKE3R[7:
M]%MH%WK%K32(45G.Z\M3BRL3F)$JD01L3QQKOBS$\;@O!4'C:`5.<*M37P/I
M<=Q>S-D78.)"<L[MQN!SR4U87"[M53YXZAPWUUJ<6M4Y];`#T_=MBK[-I>DT
M;RV=LMN4<[5"X>T)ZZG<A)<)&!5,"4A+`19IB&Q6*V>%I,6.U2\I/STOT^9=
M5D9N8=NY"0?+IMK<D0SITY%9=0X-TR%+N.P%*`!P#7:$=B\W/%<@3[L6HM[M
M7=_#3=?I-PKKW;3<V25%1*L[*T9OPB1A\69V2CZ?3((_W;L`^3_V=QYV^8*S
M'_+XCMKS*EX_2&P8`?!%X.4+2QRNLC*&E*6BWJ!D1M2Z4_&4-T5R1_;D?JR7
MUPNHQ7<6Z^*7_P!`XE_[SF/^2)ZF:??YOAB6J-WG^"(7M3$2T7:80GX>JX"Z
MB)F;ID'?HUM8<3IFK-C=RS.+<*#)22#9PHYA7T=(%69&#G)LL`";@;<!VU!4
MS@#*(B0Q.,4HNV9W5CJBM$J]#J&*J2\DTIB:A*0O++J6:4CT^6/=3LK-R$I*
MKIL"G'ND05*EZ0[@.H@2\L0BH'4A(R*M-Z;X520?*0S;!->EFT29TJ:/0E%Y
M";;KR"301%$KM9$A2"<0$0*&P;`(Z0BHV8F>$2U;I]@[O,978%884KTA"-J5
M#U%[7B>_#IZO-2+12POFKM.;<R91*Z.4!^<+V;:AC[L(\%8L^UIOU`5?+]5B
M9N4C82KP%:FVMH391LY909UIQ5)Y\X7BGR[0LM(1RY3)+$/N50`X@`!J,L,8
M1YF\8RQC)8^G,HX1L=B4@H&7C(RZT:]M6"%GJY;*+IM#R"$E%@,7.12C@ID@
M,H/K!1`.8P<=0GN.V$>_C?@MZH9"DPTI*SN/\\HU:`H4`],W9R.-KFO!-/>^
MM-5S$4":@):1:ID1$R0B@98P"(\1T,QC\6(X>>+0'S=U'O9!D]1,@]8R#]D\
M1.IWIDW;1TJS<$,?]4)%4![.&HQ"+R&MVBZ3TLX97D\9T3(Y7V1,J%11O`3Q
MTXPR)8DQU(TT)+Q1T5')5!(<3"8.4`VV'CJ&TD1'='P^I04[%$80ME=.G%X?
MMM;<'JE(CFS=C"8^L;>1289!KS0&J0F>+K.^5QZRJ8ZQR&`3&X;Z#A`\8JGU
M!O<%PV>QE;!8,XQUHHZ5&"`+58RB'A86-@H*-?0B-9=/Y!.00BE4R\P"8`,8
MZAQX[ZX*1G`GNALV1Y&IV:`NUSZR;E5X]Y%0-IPY>IJ-8/DT4G:*$G/5QRH9
MPF@=5(%EES&.;8P@(F'7#L4C>83CC51Q8ETH8=9WI_?XYE.7[),LY+C^,K4@
M@_L<>#%BU&RDLR[7OE6\0H3U<`+L)!/N`]NNZ(1YV47JN;;#T[8@P^^N"$M6
MV\E42VR^-XUM)D9+S"MA8N0&ON%2BTK+(%>Y(0`Y.!0-K@XLHV2,XB!./>X:
M:8,9VW*L?1YK*MCM@X?RRR>6"S?@FUJ$ZFWA7/OB]*T9)K3[A!VZ1*HV[]7F
M`VPG#?AKJ+RCN$1E%",<WG&C[&RV',RL+,UJQK6E>H"STXL<ZEZ]+K0Z,1($
MEX>5*+29AEVK<J@D*0'">QN4W';4STQ#=%>L)XR:XJZDC1KZ=&S1),-7/(U$
MM4*U,1]+P\A37CV`G8-C*$[N/G6#4%"D1.;8JQ/1]$=M0F93$(IQ4KET]46*
MR0%;>9JL3[(^/[#4E&%CA:*A$/'4L*$C'STTM&2@/7)XR10!8@[&.FJ8_9OM
MJ,0BUDH"!2@8=S`4H&$.P3```(A\@1TA%VG0Y^5%C'ZO/?S?D=2E3^41Y%>\
M(BGUT_A#WXC+\?S\O-'^I?'_`/QE@UL3\*W\O%?XZOQW(UE>,'^8Z/\`3I_$
M;B$9,Z1!YU.<.[*8P=V8"#Z("81`PAP-YO..LI:I]IMU*JE)'9B8R;\-\Y\=
MT8L(SB;=/E*7)":MWH(PPQC*%Z,R,XW!?A?X\MEA:KP[*S=0O6-;&$B_9$3B
M*[CN(F#4B,7154'U=,DM.%5(W,(F4,8P@/:`8"Z_0_?-3:JN;+;[57_D*=HY
M5#\M42<(*9GU%C?*0$XV`Z#8:M6D],4"%4KK`-?4/`J3,EFD2ME*LV&53B)'
M#-(X;HN%PGU`W-0.C>=M60&:Y7&*.KGJKRJFJ2LI";&RSQ\7&^/U`)&)*-H5
MNM)H']10%%90S4HGYP`V]!7FPH=I;MV3;Z76:JBI$2[4A<DJ2MU4R9KP2K-Z
MH(,A*0BOK->:ABIMCE8ND4NHIZNH=!#,D`J0I+:<)Y1-0`5,D>6*.=#-P/CV
MA]#3!E88FM,<HS'5AUBYE;M2U]-1Q2&;>70KE9?G<I*KQ[&1-)-@%JD*)SD2
M`OSH"&JQUY3UURKKRYV;O9)[A04P&<XJ:9=4X1/U\Q$E#`2W&*0T0ZQ;&;*E
M=33'JUM8_F"-H>?:2WZHZF3K$>L3*6$H])CN^X^R1;/#+K'4/(5BSSL[5^HW
MJ0KD7-DJK1LRL$X_.&&:4V.*3&"CQB(MZ7U%L[Y""X;D%41$HB/G7"BU#:Z7
M5CEJ[9MIIVCIR2'"7`EY(<)R@DJ2A6*AM&R<>A;7]/W:HTPQ=EL.O/"LJ`EO
MLDE*BP2E`*Y)"2I&`6=_2#'9@)Z6O?5AC7'F4L:R+;)&#.GO/>6L+3.?LAXB
MO.4KSE&?ER,JLRG9.EOU*+#Q=<-N>&CS+)J(I"580*!!$)-FV+H-'&XTE>\F
MAJZYAFH0TT^A+39)#BTA2"2K*#F4"9[")B)E5515NKE6UR@8^DJ>E>?ITK6R
M77%H`*$*4E?9!))$A,'@8[E8NF20SUX8])R_E)"RW3$V$\^=2F?[&E:(&3!Q
M/N6$HT3J\C+02@1$H,80/4`2)SF,BF`<QB\1G*RV6^FTYJ*Y6ZWO,L5E934+
M`RK`2GLVE%Q(4<W66%*F>IC,`81"BK;M5ZFT[;*ZI:<[K;JFM=S%B1=34/(2
MVJ0"2`VI(PZQD,3O]+TQS,HYK/21EJHVFM0.'+LEU,]1_5.\2FZ8V?Y(R@]4
MF'E0Q_:(R572GI,8@"@+9,B&S?U(FX_.[^7?J.K?J[K8*IBL<N]/]'TEO7E6
M>R9%0D.*FG`%:%*F=AV'9$YIZH3W2SW]E=$S0U+5PJZY!R'.ZNE4$-B<SE2I
M"2D*QQ.TQ9M6\DVF8Z"^F>6ELANF6(L_]>=[E.J>086F+8EK^-+M?7S8]"L4
M4=<\P>`LBAP%VD@@;E2,)U#$(83:KFLL:Z/F3<&G&:E=^HM--KI%94D=Y13C
M*9G@J21(3Q,4917=3O+&@"ZBD38*W4;B:I`,EI8+Y'5`'R"3UIC9'>\7/(4Y
M3<0V_$[''=E-BO(&6:G\'=GO%UQ).T^HUJC5]$85CTZTG'+QW,52H2C-MNNY
MEBI.3F4.4P#N4=3O(6PT5TU%3WJMK&4W*E!+C24525.K43,U"G$Y5*29@!!"
M4D882CP>?E_J[;87[30T-0*"I"<KCBJ0AM"0)=D&5E02H`'K@DSXSC&X7+RE
M*'*(`)A$!$2CY`X!L.^P!K.:H*P2V0G)G*@0>.$MLY"6$^,8))DH!<QFE*0G
M/#>9X8]$9$OLWOY1_4-_4C#_`,^XS6'WB]_A*U?O%7Z%<9L>"?\`B^[_`+M'
MZ9N,PK6`,;'X:0AI",9+VGO"[VX=+F%LT1K('1L.93=PDXH1,QE6E=RA$HQP
M.U#%`0*U3L==CTC";8`.N7SZMKS-H>\6AFJRJ(:>Q(V`$2QX8D1LQ]F!KI%E
MYNW?0=2XVEF^VD+:"B`I=11N32A`/K*+3[RBD3,D$[`8@7\`/*K;&/B88GCW
M[I-I'97J>0<6+'6.":2K^7A`L$"U.8VQ>9W.5E!(@=IE#E*'$0U0?+>J-/J%
M#)&#B'`/+U9'T3C/KVBNEG=4>&ROJZ=M1^BJVFK)Y2>JA?=U`$#"27E$G<`9
M[X_11(8!$0X!L'9V"`<.T.T-9#$3(5T1\Z23B1TGW)??C<;YT=1&V(J,A,B?
M1%I_7#F"-P5TA]2>5I)R5NE3\-7I['FY^[.I//H)U#UUHDH`C]/?3\@V2(&V
M_,</)J0N]1W&UU-8L@!MA:L>(22(N/R:TD>8?-/3ND6<Q57WBF:.49BELO)[
M5<ACE0C,5'8D"9V1@)>"9AR0S)XDW3@@"`NF./)Y_F.SK+`)R)LL?12LFR<+
M#^H,K:7#%(@CVJJ!Y]8]Z*I_I#5[';`E+14Y/IW8^4Q]!?CEUDG0/A@OJVG$
M"JNK+-O:25":P^`V[D&U1[/.<)[)G`&/2>/&U2:>*+U&D1*H4KAOC1ZH*AA/
MNN\QE5%5.7</1)N/`O8&NS7W\4/"?Q![QG'G>SX>[;PM:="4*`#]>)RW]]?V
MQ,92I<.NR\>%!X=;1RJ_P5A3I4POU0]5$<@*A65G=5^APAZ51)@0$2N(YN[=
MLBN&YRB"GOOS;;I%'5<4SJK_`%%IT^TJ5)2TS3SPGZQRIRI(X3'NQ@]JFW.<
MAJ#FQXCJE'9:\O6K;G9[(XH`%#3E4Z*BI9,IYDI*I*&Q3.W$Q<A[2[?!IG1)
MB?&D0"3-ID[-\$T=,42`V:IUZ@5F8GDFB""92I)-V\LHQY4P`I```V#@&O0Y
MINMHLK5$D%(6YA+9@#]WDBW_`+,+2CMVY[W'5;PS+MEI<2XXM7K.5+I`65'"
M:B'-_1NB@/LLUBEQH_6)4CN%30D=<,3S[%N945&S62E(6V1TBHW()C`F=VVB
M&H'VXF*B7S:\OE4I2:.KHE$J0E84GRE($O<G+IBY'M6;-24NK=*7ADSKET53
M3+*E`YFF5I6@X;PIQ8XQ9?[2;U16&^]556Z9&#XZ5"P14H>QRL80X@VD\DY!
M8C)JRKE$#<BRD-4CM&K<1#=(5W&VW>#OY_,B[NNW,6II1+-.P%K2#.:ES`G+
M>F1PZ8O7[,#E526'E;7<U*YIM5_O=4IAEU:1F33,'*`T3CE=65A9&$VTSV")
MQ?`=Z6*SBCPZZS:9.`;JVSJE0F;]=GI4^9^]IDF,A6Z5!&6.03@P8U5,5R)@
M/*"S]4X<3:K;E_:&Z'3B*@_]U4@J)4.G!)WRE+","O'CS<NVL?$C5LT;I1:=
M,+:8HVTJ46VW&TAQQ:,LP72[@3N`2#B!$4KOV7[*P9M$T9U"X^;]/I;>1^D]
M=QUG'*K>EC)"X"&)$EC!KJ]F08E!N5V,@1N8X=\)`_:]4:]RON3UY[T*E":,
MN!1`VX$*EA&6U/[4?3K7+GN9TY<5<QNX!HE2V%4)<[/+VA47`YB1UAV4Y8'#
M&+OO:,^JZRX&Z=<2]+.-YF3@ELZH2Z=UD6B[A.35Q7C]M#QQJX=\'(KW5KEY
M1$CQ0#%%5NU43W$JIPU4/,B[.6VWL6RF40MT$$@B>24C([>@^6>Z+.>SIY3V
MOF/S/O?-;5+:7J.PD+::*,R17U:E+#@1(@I0A*RW(X+EEQ$XIM[-#T?4M+&N
M1.LJRP4?*7B8N,KB_&,@[01=#5*M6XY@M;)&%[Q,PLY*PSTH+595/90K5F!`
M'90X#*<L++24MN=O"I./N+(!.Z6T3.\GWI15/M/><5_K=9T/).U.J9TU2TS=
M56AM60/NNA79),I2"4I)RG`YI_%$2;>-MT?4OJ7Z',JV=Q`LCY4P/697+&-[
M-ZL7WY9)5=#WTM]8]?3(+I6(M%:;N2';"(IB[*BIMS$`=5-J^QT-WM#SKJ)U
M#*"I)3BH$#AMEQZ(Q>\$O-V]\J>>UEMM$XX=,7JM%'4T_:%+3A?FAMU2299F
ME*203M`()E*,:SP'.H>TO+[FKH&FIA5SC'JMPKE>,JT6[7.JTK.42TB42%]$
MH*',5I^%-8.Y3>D3V*JNS;G'TBB;5K>6]PJA4JLKY*Z1YEQ:$GXLYF1X&6$O
MO1LP]H=RNL_T1:.>]`TPU?M.W:D%6X@!)>IG*A'9S(]92)I).)"<PV&,?N8A
MY&!?S%?>I+,Y:$?R4*]0/N5=G)1+E=@Z2-ML)%&KMN8H^4!+J@`7&%N-*F%L
MK($_[ID?01(C=&QNBJ**_6=NIMBP]05M&E;:QB%-N(FE0(P*2E4P1@1C'ZJ_
M1ODJ-S%TH].63XUTFZ;W7#&.IDRI%.</7SU:,;RB(FW])1M*-UDS>7F*.^LJ
MK54]YM=.^N0*F4GTB/D]YLZ>3I'F?J#2Z04HH;S6,(S"1*$5#@09&6U&4@[P
M01A%?YN*:3L8_B7@N/5))@]CG0LW3EDZ!J_;G:N`;O62B+MFN*2@\BJ1R*)F
MV,0P&`!#T%@J:4CXBA(_V10;%0NE>15-`*6VL*3,9DYDD$33C.1W2(XQ2K#6
M`\0=.M,;4#"N/:YCBHMEE')HVO,P;&D'[D15=RTW(+F6D[#-O5Q$Z[QZLNZ6
M.83'.(B.NJDIZ=AM+%.@I2%3V;?*?=CVM6:PU9K6X"]:MK7[E6AL(':+.5II
M(D$-IP2A```DD)&`PG&!]XG)XF(\<RROX5-L(HY]Z;)1^FV/R@K-$88Q=2":
MBA1`I'9CD)SB&_$>/'?5@M3I;:UPIPG;4,^GM4@_=PG'T`>%]JJK/`:R*Q)0
MA6G;LE).PM2K!@>`.P[,(D[]IBZR;77U,;=%=(EGD5!6NO#E3,OJ2XME+'%'
ME'471J<\,!B'/#E>Q#Q^[2'T'"B;4IMRD,&JHYIWRH;9;L],<JE)4I9GM3E(
MEY%3C$GV8?(^RWFLN'.K4E/WARBJ!1VU*A-L.Y%*?6HD8+0%I`.X*V8B)//`
MPH>/L.^&'B.[`K`0/X?HW;*N2+6\79L4CNB6*::E=STRL+=--I6*]!I(E%4X
M)MTD3"&VYA&J-"TE);=)4[S"`VZZWF6K;CC,JZ)?=C&+WCJO][UQXJ;Y:'P]
M5+I'V*.B8&9R?S2%Y6D#%2LY."1,X;9",4^JV1+JA\<>$O\`TZMG+B$N76S%
MWBK/8I$Z"*E3K5N:REEN*PH%$C:,?P<0[D%1/L!T5>4=A.(#:JG_`-YYAMU-
MO'S/?"K#9E`Q5Y#(X],;9[G2,\K_``%/V7F"I#==2:)-&ZV2%`53M.IIM"CC
M\XAQQ`R[01NE$D/M3C93X5NCUZ!"B@?'^66I5`X&[TMEJ;@Q1+L&P%(J&P^<
M1U5O,])[Y1_@+]Z,=?92U+?V5U<V>NX*^DV8_P#16-W3AY<(MNZ8LUV]3PKL
M/="F'999CF#KLZS;KBQXM&J`,I`8B[O'R%ZE``AP.W;RGKR+543<I3,?6N/`
M1#QK;55#.BJ>P4:BFZ5]4M(`]9*`L9R4C$=6<C%5\VM&VK^K?4G/+5M-VFC=
M$:3I:X)4GJ/5X:<[L@*/5*DE,P@SF<N$9*7B$1%/Z*_"+SM1,81Z5;K='P.W
MQ!4$F:"+;N_PQ=1=`/(.N4`]8DY52?7=NU#`)UEUE#F`1$1U<^^]ULNEJENE
M2`EFED);S*7OF-:/A[J;GSF\75AU!JPBKNM?J$5CZU@D$!2W@F4I)2TE*4A,
M@$R$I"48POLV\M(Q/B(.89BZ60CK'@/)+289@8>Z=H1;RKR<>!RCP,*#Q`IB
MCV@&_D$=6JY95CB+\TV@=2H87FZ,AFF?#:?1&V+VF]CM2O#>:]U`564MZH^R
M)$E-I=#B5!.\!82)\0!&2]XXW699^C[HHF5\?S"D-E/-%A:8GIDPT-W,A76D
MG&OI*X6..6`#"A*L*VP72:*AQ1<N2*%'<FKEZZO539K('J'"J==".D)5.9`Z
M`-OGC5WX(.3MAYS\]:6AU"VEW2UFIU5]0TJ<GBA:4LM'9ZRU!0!P4$*3(@F(
MH?9=,85.18]5^;Y"/;O+XQFJ+C:(EW28.)*-@I6/E;--^KKK@HX16G9'U<'"
MF_,MZJ7<1X[TIRLHZ5Q596S"WE+DJ>)V`G;QG(\8RP]J?JNXM732O+VD`8TV
MBB75%N1;;<(6&FTK0)`J:2"`)83!BPCVC++&/<M]=M7J>-U6%EG,68IAL:7J
M0@12D`?7EW:9Z=3J1%FG.#Z6@64P@W62+S"BY7,B.RA3%"FN9CS%QOS-';Y)
MJ$`)41M*E$`)\VP>6,@_9JZ/U!H/D57ZIUFA=-8KK<''Z9#H+:$L--36ZDN2
M'9N@$E6R0F3&:1T@0MLQOTB].U9RN[]5NE+P1CF.O[F4<E*9A*PM0CRS!Y)T
ML)")!']V<%CG$.3NQYMMAU?"WLJI*%KO"A)#"023L(`G/T1I%YEUU%?^9E]J
M;')=$_>JLMAOK!0<=66PB4\V8$90)YMTXP"?%QZX'O7GU;6:RU91R]Q%BEO*
MT#$;=N@*A%*K#O3K6"ZN>X`_(:W2J0N^<PB5-B1L41`0-O834^H!J6\K+3:N
M[LI*4F1.PF9\A]$?0OX..2%#R!Y/T5%=W):QOJ455<5&24ND`LTR29#M4H4!
MD'6)F91E-^SL9-P):^AYK1,7U^)J>3\>6J00SK'@Y3<3MJL<R=5U`9!=.%`!
MVXC)J!(1LW)^U,CLE&Y-@+N:YW+5VB7IX-M9>\-F3DI8J^4?PMT:J/:,:3UU
M9N?SMZU54/56EKFQGM:S/(PTD`+I$#U0MLS4O>0L3Z,@-+E`H[&*(<QAX;!M
MN.^PZK]1*C/HC`%J81B>J2<ODW`<91R@8IOG1`?E"`_I:XD$;8[B"-N$:ZA$
M(:0BC>7OX-!_QEU];1U+5&Z)FGW^:*($^<+_`+)?T@U+Q,QR%';TM]A(`G`1
M#?8Q?3*;;;TN40[/+J#KRRZ%;N,2(I&W.UID3[!04)G`]=.4RV;C%J4=TE5B
MOKV(*EE_/U*C++8K!9Y."J.49Z"@E)FT/5I&:=H1C0Q44B/E'(\P;=N^O;36
MY`V"01B?)L]$6&3X>+72U-0U9KQ>;>P^\XZZFCJ13I<4^HJ)7\VH+*<92Q$S
M/;'7K'2#!4N#CZS3LX=2M8K<4FHE&04%F>Q1L4P3675=+)M&2*I4VY57*YU#
M``>D<XCVCJ8J[@WV8RR)B7I/#DQ9+>FU6G4VK$(9*R)7$`3<67%2DR!M49RC
M[I.FU5,Q1)U%=5:9B@8"G'.%G,!0'M#E[X?GM=(O1;Q#2/?COJ.1M2J24ZDU
M:A#<Y!-R&.893L9CX->Z1*_423"=6S7U)0)+!.2%GG2PN8;#'A+V.5[OWSG)
M/NCE];E)#N2=ZJ;<Q^4-]=;EY54D!Q`3EV>>)>V>'AFT!-)3ZBU6W3NNK<=R
MW)/6[504J<F=NW;CC&LQTB5^PR-<EI[-W4G+2=1D%I>K/9/,-D>.J]*N&BK!
M:1BEE%#>J/%62YTA4+Z7=G$/*.IMBO;"9X".RZ^'.UU[R7J_4FK7.[8TW^X@
MY%;S^0,L2KA'W3=-BBB9T%.HGJJ%)8ADU"*9PLYTCIG3[HQ%"=\(&(9/T1#S
M#J1-RQG*)Q?(Q\TSE$_J?5I:4C+A<@<#A_\`#'E&'1G48BECCJ*S#U$,J$$)
M)0!::SR]8VT#[S21'`/XA*-*?U4&;XKI7O"B&QA.(>77:Q6!YY)49`<8\NG\
M.5#2V-5C;U'J0T0S!2':OM4K#NT`!I(W'-MVC9%S]/JT91JE5Z3"`L6%I\!$
MUB(*X6%=P$;",TH]D"ZX\5E0;H!S&\HZ\ZH4%5Y4)99;=VZ+\:8L#&G]/,V2
MVK;>[NWD"JALJ)$Y[24;X].C^W(_5DOKA=3$346Z^*7_`-`XE_[SF/\`DB>I
MFGW^;X8EJC=Y_@B%[4Q$M'L(._3$/1[IC]NW:*PUZ?5Z1E5W2.[U`]97<+LB
M-E$N1$.]7<&$VY1]$`TA'C3@7E,80`P@(&`G*'I`8Y`5$1V\B>_#RZ0CV5QO
M\U>6U*92J;(J=%J;"DQ)FK44>^AXQ9X[2</=^"KA15X)1\H@&D(]S7<U>H5>
M&J=ZQM3,LQE4!1K3U+4\GXJ2J\6\65>NX=I*5I=L^D8LSQ05$V[HQTB"(APW
MTE"/*%R!R79:XFI%".Q5**`TD:XG^!R<<"*20-FT:!O64%R)DX.2&*N"FYMQ
M$=(1Z:UYC1G*D\HU0QU4,6UF7E&<Q9FM5/.R+^T/(U,QH@9*1M#IXY-&QRZA
MCD:(B1,#&$=);X1]^$SZRK96$Q#86Q=&Y!B4@"'R*P:S+-['/6B(MT9I.I-Y
M`:L:;03-S)K=UN4P<Q?3`!TE.$6^*++/'#AZ\.JN\>*K.GBZP!SKNW2ZKEPN
M<.("HNLJ)Q'R`(!Y-(1ZZ8OLO+4.IXW7;-$H2G3%BGHMR@D/KSAY9B-TGJ+E
M1;G;BFB9N02>B&P?*TA'..0II;&9,6O&;-_!,K<>VQ+E=(GOE#R;UN#"3:QC
MLG*F6+D2HE%5,2@&_I!Q`!TZ814M#/R+YI%#?\1T#)UFA(QM$QETL_O^WE18
MQJ0-XAC-L81VVBK`E%(E!-(STBASIE`##L&DH1XRAY<D:)8[3-EK-=L$==X2
M8JUGI[MJXB:VXA)LR;A9BR&',E(QI63EHGW(HG#D``XZ0CLT?+J]6@Y"G6"D
MU?)%!>3#B>;TVV'E6[6OSAFY4/?*!FH55O--E3M2%3<"!@(N4H>COI".H]RM
M(-;Y5L@4:I5'&3FG+-CUV+J+)V=L!T!4.9657ESN)&=</`<'(HHX.`BF/+PU
MT/`R`$S$1'MQZC5HUW,OJ5B/&E!=6>"GJ_;G$.UEWSF?;65FLTD.Y<32KH:X
MT275!8K6.[M(RH;#Z(:Z,JN!CE./%T;(=>J\+[PV?#V/,DM$U3/&#V>-.04X
MS=+E`SE-27JSAJ]?QB@D#D07$Q2!OY]3VZ.$<TGFV_.\E1>4&2\=!6"!;1\=
M7F41')>\4)6XUBI&M:M&,W8JIK0?O<J9%1-8.=4#FW[=)"$?2M&7*]/0DG'Q
M&"L7TV8FBAZ_:(=&>D)!,%%Q77&$CIUXYAJTJY5(8#BU3`J93[%#EVTA%&?]
M'R.W;]'AOI"+LNAS\J+&/U>>_F_(ZE*G\HCR*]X1%/KI_"'OQ&7X_GY>:/\`
M4OC_`/XRP:V)^%;^7BO\=7X[D:RO&#_,='^G3^(W$(A3&*?<`#<!WXAOMMQW
M_0UE2IPJ<#@`*DC8=L8H%K.`C$D\-\<QU%=^4XJ$`"F)L99;<A2`!C)`'>`*
M9!Y>)0V+PXAJ3[0O*4EMAE#;HFI91,$M==(F"!/-LQQ)PQB<8JZE*.S6Z\0@
MR2`K++-U5;0=HPCN(D<.E$VZ)573IT8A$TD2N%G#A0VQ4V:229S'6Y^?8$B@
M(".P;:[JSLVZ53KZJ-"'&BXLJ3E`*1AFFL2.)V],=E/W^LJP&E5"G2L,I`5-
M1"L)#"9&`&`CKJI+)\Y5`4(*1C`=(QU$^Z,D<2'0$G.7N^0Z6QD]@XEXAPU+
MII+<7$N+;9*LG:'9UB.J)?\`+B.B.2ZIYK-3]J^%@Y`#/!.TX2V9L/+'$8QC
M[B<XB!B)J"8%#&%,G'E(``83D3*7B!2B4`UWH=9S'L$94/I#KR4X*,R2$JZ0
M1.1'FC@XIQ`+*G"MQHEM"5`[,!@3@G;O'1&A4DA[TVYA.L8PF7*<2J&$""4X
MF+OZP8.[-Q]+YW@/#7)+++[+E.YVG<E*"RB<R)3/##:=HB!K*MDH4B27DIR`
M2.(,AZ\\NT"6$;P.**7(GLBD8P`44N\3Y?1,4$RBF<HD(H3<1+V&`1X:\R3:
MZ9*>P8725`*LLTDI4DE`S">!DG>!M@*NN#K:F7'A5M(*9A?Q5*S$)D-DSTXQ
MQ*`0>)BD/S'.IL7F+R"J``IW8@?8@J`78VVVX=NN]=&XE]#[U.P5NMH4M4TF
M1S$@8'U@1,C:.B.3-96AON[+[S+;:)!*E8$F85PD"-T;1-S&4,!2[*`/.`CZ
M([ARB;DWY.\Y>',`<VW#LUWK#AKC4EAA1*,JEF68B4I;9[((J%)HA3N5#LDJ
MF$">6>V?#;&_9,A^\`I3*<G=\ZFYS%3`3'[LHB/HI@8XCRAL''LUSIV;9184
MX223/%!(F?1$N[6W"O5_F7G%@<5;O/&PYN;;YWY10V_UZ.LMI/;(;ID%6TMH
MRJ/X6)F.&R#SA*$MDK,N*PH>8`81D5>S>_E']0W]2,/_`#[C-8A>+W^$K5^\
M5?H5QF=X)_XON_[M'Z9N,PK6`,;'X:0AI"*%=2F":9U,X.R?@C("(*57)U/E
M:N_7!(JJ\8X=I"K$SC(#"')(0,PB@\0,`@(*H%XAJ3N%+3W"B7;J@`I>24B?
M'^S;%7\O]9WGEWK>V:XL*RW=+75(?2099DI/SC9.Y+B)H5_=)C\RS+>*\Y>'
MAU7'J5D0<UC+6";_``UNJDRF@LG&3Y8270F:E<J\ZX>NUJPMFI%BF*([`8Z"
MG*<ARAC5<:"Y:2O"&DG_`#+*\P(WH,I>D81]-VC-9Z"\3G)QRNMQ#NF+[1N-
M/(,B6ZE3?9O,E)G(M*/:#=,`B/TB>A[J[QSUM=/E*SGCQZWWFXYNUNM;!<#R
M=&O;5JV_".IS"!C=\BLP>'$R!Q`".6ATU4Q$I]9'6:\TU]MC=?3J!F`%#@H;
M1Z8^;7G1RAU7R1YAUN@]4M%"J=:E4[DC)^E4J;+P.PYQ/,!ZJ@1NQNZ6,!$C
M&$=N78=^/;S!MV;^77I*2M8RH]8G_C[D6K4K(A2SL"2?0(Q$_:1NO:ON*]!=
M">.YM!Y+N)>(O>?G$<X(J6"810)OJ50'JJ1Q+[YOY!0DL\0W'N46S<#@'>[!
M:7F;J4-,BQ4QFZ1F7CNX??C;9[,[P]UM?>G^>FJ6"S9*=I5/;5*&7.X[U''1
M/:$"8!XS(,7-^SM=!TK@?!]BZI\D1#B(R#U$,(MO1XF3;`WDZ_AU@J:0C'CE
M!8H+LW5\E5/7N3T1/'HM!$-S#MZW+?3:K90?2=<`:U[%.W!&[T^Y%L?:)^(*
MBYD<PJ3EKI%W/I;3JE!^1FERN5-+J0=_=Q,)(F)E0&R,?WV@&,/'>*-G`Y@-
MW4I6,02J`G``YTU\95MNIW>W:FFX:G+OV[AJVVO4RU4]/9D'PQL>]G,^7O"S
M94[A6W"7[8\?AB:?V9#!<HGC?/753;#.G,E?INNX:H\A('.LZ+4<9QR"\P#%
M98?0C%)*09LB%3]$OO5R?J-@K_EI0K9HW;[6RSN'LD'^X@R'3MV1@A[3S75&
M[J^S<I[(4MVZVI<N%4V!*=95DJ!)V',DK6>E>,=KVI*O/W.`NEBSHE4-'0>8
M[E"/SB!A32<6>F(NXU50P>B4HA5UBAY]]@USYII*[93/)ED2Z?=$ON\D0]E;
M>Z5KF+J6P/D=[K+13J;!VJ##[H*O2XDGRQ]/V7.CGC.F_J4R*HGRIW'-,!6&
MIS"',="D4Q!XJ8`#CR"XN(E'SB0?-KKY6-@6NK?&TU/O(2(E/:HW@/\`-?3M
MG;)*6=/]HL;DJ?JG@5>4AL"(*?'MK#*O^)]G5ZRG&$P%P@\:VAPW9R"#US`O
MST:%@G4%)HHJ'-&/6XP95BMU.4X(N"'V`#:HGF`D4VJ'W@0>UIVSY)9L#TB,
M]?9WWQZ\>&&STU93E@4%55L(F)9P*E2PX.(/:2!Z#PC,X\'R_0&1O#<Z19*`
M>-W)*[B.'Q_,)(&*8S"QX^45J<VR<`01!)P5U&=X)1X\J@#Y=7ITO4!_3M&L
M;V![F'IC2=XK-,5NDO$1JVV5Q45N79Q]).]+Y[8$=`SY?*DQ)*],F@T<+J*$
M2312.JHJLH5)%,B8<YU%E3;%31(4!$QAV`I0$1X:]Y)2DS5@D;?)&/*FB^.Q
M2E2U*(`2GUE&>"1TJ.'GC`?\='-\QUG9(;YZQ9474ITK=/5F<=+43FQL`F@K
MYE.2(YN=G-#JAN1S6&GJ96;-VF`IK*)";F^G$+JQ^N:EV\5)KJ!(<M5--I2M
MO6)D3Y`</+&^[V?NC;=R=LKF@=85:&>:VH:=N\JH2>M34*"FG92X,"5K[4DI
MQ*3/<#$V_LT^6J_:NAJSXI:N$"6K$68[.,S&F43];&%O[9A9("6*@014]2=.
MB/6H&$>*K0X;\`#54\M*A+FF13DS6E]0\@)F/N^_&$?M-M.U]K\05/J=Q,K/
M=K/3EM7%;(4VI/04@IV[<T2>^)QENOX3Z"^J>^6!TW12'#UOJ,,W6.0!D[1?
MHU6F5N+1(<?IBSN5G$PV`!$I`,?L*.JKOU;]'V&JJ2<I+:O=$HQ=\-6E:S6G
M/C2MDH4J4^+W3O&4^JVTL.+42-@"4GSD",+CV?;#-DR9XC>.KA&,71J]@ZHW
M+(MFETP4!FT,[KCZE0<<X4`"$!>7E;$8$B&'TR-U3@`@F.K+<M*9^IU$*L'_
M`"S#!*O^82'OQNK]H_K&WZ=\.-58'Y?2%\JJ9%*-ZBRI#CQ/0D(4,?-'T_'>
MZ%ISI<ZN;)F"N0BY,']2<P_NU:DV+7:-KF1GH"^O5*>*)E[AFNM(F-*,2&`.
M_:N3@4![A3EF-=V-NVW@7%@#N-4"1T+^-Z53/E)B0]G_`,^+?S5Y8,Z%NU0K
M[8:=IQ3K;S==ZF2K_+U"=F"&\K:@)^K,^L(F3]G"Z]8.XX;>=$-[FFC/(^,9
M.:L&(V\D[[@UNQM+O'$O.0D**NP/)2D33E94S<H\XQ[PAREY$%!"L>7%];J[
M8+76$]X:40B>]&$B/(9B,-?:4<A[O8=?(YTV&GS:;O00BL4@=5FJ;&0*P^*Z
MR&R5'_J3^5&4JGS;FYMP[/TQ_1U<J?7*1L`$:O05%1)P$Y`?#YXMNZK^J+%/
M2!A.X9OS)/-H:L59F<6+$%B%F+=85451AJC6F1Q[R0FYMT4$TTR`;NR<RJG*
MF0Y@E*^YTUHI%UU40&TCTD[`.D[HK_EGRRU5S?UG1Z"T>PIZZUK@"B!U66@0
M7'G#L"&TXDDB<P!B1'YO4Y;LHY?Z_P"L9+RM`R5=R%E_J-QKD9["RJ2S=>-8
M9#N5:GJFQ21<E(LWCD:Y),TVG>%()FH)F$"[[!C3<7:RLOJ+G5[7JEL@=&=,
MO<E'TGVJS:7TOX9:S2VC7D5%EM.FKA3=J@S07&J5UMX`XX]X0[/IG$G'M+4.
MT:^(!6IMM,Q4B$_@:DH/X]I)-'KZ!?P%BMS0[259HKJ+1@NV;M!PFBJ5,5"'
M%0-P$=5/S0;`O"7)CK,@8$3$N/`\)[=L8T^S!N+E1R%K;0]3J0RQJ"H<SJ00
ME86PQ+*3@L;E2V;-L:]%."O$\\1[I$IG3#C6[UK#O1%CB;L$#,W&56>Q);Q)
MOIYU9I.(D&\2LZLN0&=9<RQ4DV"/J<2@;N@<*F5`!)WV*CU7JFS)M`7W>S(&
M7M-ZI;O=XRPXQX//;6OA;\,_.>OYFZBH'KYSMN2&ZEJB1E<11(D&@^VH]6G)
M"=I)=$S+JSEE`^'MX573EX=<)(S]=<N;YF.:AE&5MS-<$6#*0:0Y1*Y>P]3C
M$A&.I]7YTBF6`AU7+DJ9?65C@4I270TYI>W:;I2NF3VBI=9P^L9>\,-D:QO$
M5XK^9OB.N3%)?,M!HUMX"EMU,3V:5F03VI&+SAW$B0)D$[XQ9O'XZT<==7.<
M<>0>&TG5AQO@)"ZT!3*[<BIZI?+U).H*4L\54GX)^J2$?56K1J`N"*&%R9P*
MA`[GNSGMCS!O5-=+BTW1S4&P1GW%0VR/1.-K?L]>2^I^5&B;C5ZV?11ZEOW9
M5:*%4@^S2)P0MY&U*E2.T"6SU@8]#[.+@N1RWUI.LI315WU*Z8:/.SD.5R)C
MLF-]R;_^F84&1!`2)/%(QO(.C[;"(MTQ\FNCEI3NW"[.UK\\U"D@<`7,3Z1Z
M8\CVF.O+7I#E.G2%K*6[QJBXM-NK!`6NFHI''>H9PA..'6C)9\=>L2EF\+WJ
M52B4UW"L&VHMK>((``B:(KV0JP^EU5/1-](91Y%%U.ST4AXZN=K9/_\`EZTC
M:69^7&-97@=O5-8_$YICO:00_5+9!/%U"LJO+NC'']F2HYIWK9RI=SI&.E1>
MGZ8;IK@03`B^MUPK,8@01#@0563!R/\`\FK<<K&4N71;IVM4R2/^91!C9C[4
MC4M30<G[/I\!L_2EZ)5F,CEHTJ*9>=0!\L23^U#PS5_TW=.4P,S$-Y"OYMED
M_>-W*-F\Q*1DY2G[=60BHA10KN1;1CQ@D1=5,AB(`N',(<P`-5<SV`[::>H3
MZR7P,.!!G&+OLL:NII^;E_MS;2NXU5H0MQXH)0VIEY.5L*E(%8=)`G,Y2=T0
M-^%E->(Q>F.<^EKH(>,:RCEE&MSV6,CO%V\&I0X&&2EH5NX97%R"ZM;7G4Y0
MZ',Q;N)-4$.5OW>RART!H]_4=8JJMUC;2TRL#,[O1Q(\NS#'ALC/CQ>T7APL
M-RL?-+Q`H>J'[:Y4-V^D0"I-:X"A00M`]<)D%24>S&.;;&2YX=W@,8@Z5;7#
MYPS_`&E+J%SK%OO?F&*K'.D\:TRQG4.X-/QL=,G<2]NLR;I<5$Y"2$I4U?IJ
M;<JNR@7'T]H"ALE1]*W%U57<E8S5L23O`,\1Q.(G&L?Q%^/C6W-BTKT%R_I$
MZ9Y?.HR+0@SJJE"4@)"W$]5A!$TEI"NL,,Q&$4P\>KQ/ZOA;%%NZ-<061.4S
MOE&)&$R6^@WJAT\68[E"MS2\>_>MSB"%ON<3S-$FQ3=\V8KJ+*`43H\_'7>J
MJ6AI38J,RN#XEA+J@SF3TF*C\`WA7NW,'6='SAUC3!O05G?"Z5#B<*^I2000
M#@4,J&;-(S4``")Q13P'_#"I<MTMY0SSGBK(2#KJJHEKQ;1HN2:)J+U_",L@
MI%S5DCDW).=O)7:62!5HN42F*R9(&(.RP[R/+_2K(MM16U@F:A)2GB!B#Z3%
M;^/KQ/WI'-6V\N]!UA:M6DJMJK?6V<H=N(4%(95*4TM(P$I@E2@1-(B"#'N2
M^H?P7^ONX1<<@+V6QI97%-NM7?JK-:]F3%#YXD\CS*JE(8A$YZ#%O(QSXI#F
MCWVQ@`W(H0U!TE;<-%7QQA)*EMK*2V-CB)S"O+L(C/W4>F.7GC<\/%&\Z&VU
MUU*V]3/X%ZBN*4%*TYA\5M4P\F<E))'3&>[T8==?3UUQXRC\@8/N#-^[2:M1
MN%`DW#5G?,?RBI0[Z)L]?!87*!"*B)47J15&+PNQT53`/"^MHOM%>Z1-91JG
MF)!&\*&U)\D:`.</)?7_`"-U2[I[7%(ZEC.0S6)2>ZU*?BNLKE*2A(D8%.PQ
M><AL/.8`VW-N/;V[!Y![-M>L$N)$G#,Q:=+?9K5@!,SF#.<<^HQSAI"*-Y>_
M@T'_`!EU];1U+5&Z)FGW^:*($^<+_LE_2#4O$S&[2$-(0TA#2$-(0TA#2$-(
M0TA'*C^W(_5DOKA=>C'FQ;KXI?\`T#B7_O.8_P"2)ZF:??YOAB6J-WG^"(7M
M3$2T-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0U&$-0A#2$-(0TA#2$79=#
MGY46,?J\]_-^1U*5/Y1'D5[PB*?73^$/?B,OQ_/R\T?ZE\?_`/&6#6Q/PK?R
M\5_CJ_'<C65XP?YCH_TZ?Q&XA$.7OC"0`*;O.PJ@")!$`W`#`4##L(AYAUDX
M%*+@<'K*P/DC%9M89;0Z)YT&1XR,_OQ>=C+IRJUVJN#8[WRM9LS=15HM,'2(
M9LSCD:E6ZO79^.CEKM8W9C>^[PP>JR12,DTB$6[G<ZQ0#5J]0:VKK)<+BME(
M-EMJ6%*$]JWG"B4I&4I)..V8E%X+7HJ@N=HHZ=:DIN%P=5(G'*$!*R=O"<I1
M6FF88QGBO*=#N<?)6)"9QHIEO(5EHMU?U^0GRU?$%.<6*G9'D6E9<N$JF6VV
M51!!*+<JKJ<J0*"<2CQ\:HUG>M26-ZW5U"6DW-U%.RY+`%PK;,II$\DP3QCV
M$Z.M.G+_`$]?;ZL/JMSJ7GT\0A25GXQE/*>$>`M/2_#5V@!:\ISMB@L@6S%C
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MA?TJG`T2UY.DKJL>LV/X4<<U8B0QEVQ>=LYCHA5.[/ETVR*#E<4V*JH`<XB4
M2ZZ'.954+&FOJD!B^/UI8+)PEUB,JA+;+@G9'0.6[%7>'*>@>[2R,48>#F.T
MH!.^7NQ;KG*A4R@S=7C*=+.'B\K38^:N-7>2\18Y+'-J5D)%LXI\I9(%,D5)
M2!&35N[5*0`[@7/=;B)=5KH*Z7*Y43JJ^A[$)<("C+K#`A0P&!F<#CA%$ZST
M];=.UB44%6'5E()`PD2.$SB./IBAH@```?)[/T-56XI1&78D&***U+45*Q,;
M==4(:0AI",B[V;W\H_J&_J1A_P"?<9K$?Q>_PE:OWBK]"N,U_!/_`!?=_P!V
MC],W&85K`&-C\-(0TA'&8`$>.V^W#]'<.(;AN&N0G*.!2A2L?7$1Y]>_AO=/
M'B`TEI7,LQ;B"O%?;N"4'+562:H76FK+B"BC4JSDAFU@K3A?TEXMX!VZ@[G(
M*2NRH>+?[%1W^B["J`#J0<BMX)^##9%^N17B1YA^'S4?TOHQ]"K>\M`JJ)U1
M["J2G-+,F>"TYE95@3`4<#.48Q++PI?&'\-C(LQD#HDN;3)L*]%)NZ5QO.1;
M(]KC&JQE6K2\8CO[E*/E%6Y>WN%G@I&$>Y5+PWMA1Z1UMI9PU%F<:J&I^HHR
MD-H,E8$X2\\;.KEXNO!YXEK`U9^>ML=M=Z1)*.U0I79K(D7&*EGKI;Q(RJ4B
M8D2F0BM%DZJ?:3<M0[S&<9TV2V-7\DD$6]O=9Q-%TN8;IK@"*CME;[C:Y&MQ
M2O$3>LLTR*)=J8E';7I?3',>Y#N;%*S3N;W-_3ZQ($]@PG%&VSE-[-K0[ZM5
MW?5(O-&A86FD55=HD&>".P:':.B<@4N9Q\H15CH`]GNFXN_,\_\`B&66/R-:
M4IT]L;X?BY]S:F$I9EG)'HS67+HX.!K:L#WZ:>/:B=LNJ7_>%UTQ%(TWIS0:
MV*T7C4#@=N*5A:1M&88@DD8X[MD45X@O:!V^NT^.6?ATHOHS2X:53FN*`T4,
MJ3D+--2@960H$CM2E*T[@#)0RLFC1!FV21;HHH(MTTD4$44R)HMT4"@FBBBB
MD4I4D44R@4I0#8I0V#8-7/!))'&-63P<J"59NU>+A65J,YJ)F<=YG&+SXT?A
M`=0W6AU.XWSITZ(5:02L=,AL=Y.2LMF8UPM46K<L^/"W$$GI0/-QAX65.DX0
M:]XZ!1J0`3$#@(6RUAHBMOEQ:K*-U`<P2X#M">(\V$M\;0/!7XR-!<B.7%WT
M7S*-4%M5:ZJWI:25)<6I(^;,IY9K&;K22<YQP,9`/2/TWU'I)Z>,4=/U*V6A
M<;U1M#N9(Z0)+ST\Y.I)V6R.0`I1*XGI]XY=&+^I!4"]A0U<&@I$T%O8MZ#-
M##24#IR@"?GVQK^YL\Q+OS8YC77F+>\'[I5+<2W.?8LYOFFAT-HDD>0G?%+/
M$2Z-X7KLZ5<DX$D9-K7YV708V+'UJ<HJ+HUJ_P!77%_79!VFELL>(=+`=H]*
MF(',R=*\NYM@UY^H;,S?;0_;']BQ@>!E@?@BJ>0'.*OY$\T;?S'MX4XQ3J#=
M2A.UVD<(+C8W3'K#I`Q$YQC=='&$_':Z,<;9"Z0,*=/6/8>)MUXE;+'9VM,[
M5I2$I;Z;CVL-+355EOPG*V>-'3>-0<-BNXEPX;K%$>X'GY0MKIZTZYL5`Y9K
M:VRFG4HR=4H33,2P3OXQL@YW<Q/`GSQU'1<X-9WV[INM+1H:<M;3+@34Y%K>
M2AT]F2D3<[,D+0#EE/?%]9?9Z\47#I8M50RWDR3MG61>[.YRI8^J9<CR8>HY
M%<M5TEJ\1A)J@]F,<K=^<CI-=0CURL?UHHI'(DF3VV.7=`[9ETU8ZMV]NG,7
MCM"I[A\G<0=H$6+9]H7K;3_-*GO>C[=3T/)BA832L6,`!OL!(=L,HD*J0FE0
MF!ZLR#FBS7I&P3XU'A.2=SQ]C/IVIG5AA*S30S?O)"7F,/&HRX(I-5;+5W+N
M3@;)4G<NS13*\:.6"R*QDBF$!,7O!\JST&O-)J50!+==0B92,P3+9B`<9]!V
MQ=SG'S!\$?BN^C]47V]7/2FNJ>G[-Q;E.IYS*>L6GU!"TKDHS0H*F`")[HOE
ML&,/%[\1I)+'V?T*5X>73%,AZKD.L8\LZ5RSMD>%,8`?UI&9;O7R4(P?->8B
MAC'9HF`P]XBY)NF/MNL:TU*GL*QMJAM$Y.I!S.+3A@"/5F</)/S6*H=4>$?P
M_/&_\O57+F!S"ISFI7JMDL6^C>`ZCBFU)0I92>L@R7):4E)3.<2K*]!_3(OT
MFAT4FQS&)X!+5QK25<1,*<B@H54KTMM3FA*,@%X3F@]\??,3^L&?;G,(E$2C
M5"]/6U5I-E2@)M/9RR##'Y4_+CY8Q9HN=_-!'-5/.]=T=7K]%67P^-@3/_M2
MB?Y`H^;*-F28WQC*Q/A1^*%X8.>Y7,?A_3U?SS2)%%2)<P3J1AXV;LM2.[,Z
M;5O)%`GI2$C)=S'*ASHR$2^(HDJ/>I@AS&)JWC&DM6:5K36:;=1541_Z;O5P
MW#$R)\D;,[CXL/"SXH.7K>B_$71U5@U2VG,BHITJ<[-Z6+].M"5%))VI6D)(
MP*3MCO\`4!TM>.+XKTU4:CU!XXHO3-A6L2R$HG"2DY'0M<0F.Y4:FMTE7X6Q
MVVX76;9LUE2,T5A1;H=X;;NQ,*FNR[6G7>J7D4E>BGH[?M5D5G^^>C=+A$GR
MSYL^![PG4]=?.7=3<=4:Z>04M.N-+2Z9RZJ7<C=.E)VJ.T[RJ0$9$7AX^'KB
M7P],._!YC]=Q9[?:%FTSE+)LNU00G[Q/MFW<-P!!#G3B*W#$.=./CTSF*@4Y
MCF,=510YJ[TYINBTS3=VIU9G#+,HX%2MY(^"-?'B"\0NN?$)K@:FU1\Q0-!2
M*6D"@6Z=L'"9$@I9`&90`G*0`&VY/J!Z>\1]4.,++AO-M2C[ICZSH%2>Q+XJ
MB+MB];B)F,[!R3<2/H6?BEQ[QJ[0,55$W8/*8Q33UQME/=J==/<DA=&K8/NW
M\#NBW&@^86J>6NH&=9:+K'J+4%*X2EU!EOQ0L?':7O2<")<`8Q#>HGV<WJMP
MK?T<B]#^66-ZCX&8+.4YO+V;X,LQ4]=LH5=D#*QE]6K4X\:;F(5TBO'JJ%`0
M,CN<0&TU7RYN5MJN^6!Z;8D4I)DH8G?C&X/EU[27E=KJP'27B`M+E-4O,!%0
M\AHU-%4S&698`4L*6/6DA21\HQ=/BZZ>TW0T8RHSS&>-IM9!J$<WR!E)OBAQ
M)HHH@(%>RLS$7%DWD5R@?F%55DJLL)=S`<W`?:I*CF<D&F<;87\E:BD%,\)X
M;=F\19?4-K]F-65RK\U7WJD1VA4JFID7`LJ*C/JMJ0I36V7S2D"4@0`!%+\Y
M8YH/3C=*KU.>-WU4J=5>>(<"SN(^BC&2B#RHQ+X5?6&CN5KQ4X&":5])Z0NQ
MUF<=&KF#E54?[=T,K6TK-IJTW35]8*VO1^280GJ!6XA/$;,1TQ4VB[[>>:-G
MJ>6O@CTK]F-"._-W+45?G0\XW,I4.W6I8&9*@I*5*4[))`"!.(/<B6^\>(%X
MFS2Q5^%D>GZ]=0V=<<Q5<C')I!])8N=^K5BL5^7,)&L"_.[B&$*A(E[I-MR&
MV[L0*!3ZH`"HU!JL*:"J5RK="9RQ0/6V<<#&P33U%I[PX^$M-#>*AK4%FL-J
MJ%/J;([&L+KSW:(29J!0I:\AF3@3.<935L]G,Z99[`%PJ`Y$R!8.INQN$["/
M4U>)20FY9>UHJ+JJM9"HI2!8Y6H2ZS@X/"&46DS;$4];,HF`#="HY:6!=`]2
M*=>76O*![51F0K=,;@3*8!V1J9L?M'N:MMY@4%X-NMU-RNHV33_05(E+:.[$
MA(4%Y<76R,[:B`F8D4A),K-.E[%GCF>%M%3F&L9=.6.^J'"B]ADIZ(9,;/'2
M<>RE9,4B/92`D"V2GV^#:RXHIK.&+MFHD18#&#;<QC>9;Z?7VE&A:[=24]91
M#85+RR_X^>47>YOZT\#?BIN=+K;4]\N^E-<-TJ4.R8<6I02#)M3F1;$Q,R*"
M,TY3(E*X^R8+\:7Q*1+0>I5_1^@[ICDU42WNI8ZD&S_(MNB`6)ZU!JJ1T]8I
M:02<)D$"D>OV,<(B`K(.0+R#Z/<]>:@66;VIJAM)'62T<RE#>)[N&V4HMO;-
M=>"GPY2U'RS3<M>\T6D*[N_6H4U34CA'57D4AL'(<0H(6L'8H;8]MXE?@S,L
M@=%&"\%]$]1@XZP].=P?3,-`3,W'Q$A?8NXQ98R]2$W;),6S5Q;Y.08LI$ZS
MHZ9%BMQ1)R$*F0O?J+1M+<+"S:K0`ERD(4DG#-+:2>.^>\QY?AD\:*].<\[W
MS*YY5U0];]0478O/-))52]F<S+#+:02EI,RA*4B0P)VDQ?-X17A_N>@'I=84
MFXJQ+[,]_FE;YEU_#+@_C6\VJW28PU5C)+E+Z[&U6'1*EWQ=DUG:KA4@<J@:
M]C2=@&GZ'(^H*K'C-1_%'_*,(L;XMO$`[XAN:'VIMZ5MZ0MS!IZ%I?K93BXZ
M1+!3R^N09RPB1'*^-*QF/'-^Q3=F0/Z?D6HV&F6-H4`!1:(LD8YBGO=*#OW;
MA))P)TC=I5"E-Y-5$ZP*RD<I*K%M8*?*"/N\\8_::U'==(ZGH=4659;NUMJ&
MZAA0PDI"@93Z92/03&'=@'HB\7'PI.H#+:72M@FI=1%0R=75*?%W=T_A%ZZZ
MBV4JI)5>S2S!W:JK*P%DAP5-ZTS7`S183'`#&+R"%GJ#3^J=)U]0S9&6GVW9
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MJ_Q,>$SQ:Z#MECY[FY:<U91"::A"5NMLN22'%,.)2XAP.G<^DR$\`0"+SIK)
M_M!75BP-087!&*>A2M2J8M+7E:1L""]DCXQR<4W3ROG?62XS4>Z00$W\"8$<
MAVD72^?#U57'F'>$]W8IJ:B`&+A7/#HP]&$P=\HL?0Z<]GSRFJ7+_<;[?M;U
MS9S,T`;6VRMQ)!;2I24-(4E1DE0*\A!,TG`1B^8JZ4$.I_Q$8SI8Q_>K+DR$
MG\NR,%:LO3/.67LE9JBRDEE+)1C*.GJR#>00B9!9AWRRZIBJ-N\5.H81U:MJ
MU(O.J?HP3?6L_..XF8V*)Q,L<.B-J^IN<"N4OAF=YCWRAI[1<F;4A=);VB.S
M8>?$J!A$\H(G+M0!@`<(_2^I]0K]&JM<IE5C6T/6JI!1%:K\4U3(DVC8:"8(
M1L:R;D(4I"I-VC8A>`>363B&PTA+*?40D`>0"0CYG;K<ZF_U[]UN1S5=0^XZ
MX>*W%E:S_P"HF7"(&?'.\+EYUCXX:]0&$X1%WU'8AA'+9Q!LTT4G>6L<-SG?
M.*RFH/)ZQ;:TN95Q#@<1%P55=H'I*H\M#:ZTJ;W0BKI!_N;,\O\`>&])X\1&
M>'@6\5:.1NJ%:+U@\L\L;R\E*EDG_(U"NJA]O@A<P'2,`.L=\8+=%O\`E'"=
MU0M>-[?=,6Y"K3E=JE-U:5EJI:8AV@L*;R/=JLUF;YN9%=,2K-EBB'.78Y>&
MP8_4[EPMU;V["E-5*93Q(D1@1_9&^[46F-'<RM-IM]\H+=>]-/)!2%-(J&U`
MB84B84!MF%#RSB7+'_M!GB8T*&;0SW)=#R(1N@5!.2R%C:!D9PP%X`HZE($]
M<</5A\IEP4,.JXIN8.J6!EJ'&G!/#J[!LW;XPYU#[./PTWEU=726ZXVY:E$J
M2Q6J*23C@AQ2PV!L"0``-@$?:G/:!?%%R,0E4K%OH=?EK`X1AXQ+'6(H9:QN
MG\B<&K-C"C+GL;H))XY4*5'N2"KW@\-]=SNO]5U@+%$6Q4*D$@)$_-/W=L2-
M+[/+PLZ2H%7_`%#2U[UMI4]HXNIKEH:2A,U*S]DML24,,9#",N<M`ZVOS5*E
M,^$6='KI'``2'X:>N-?PE#*6Q+-[QA(^K^I>_GJW_P"&[_N^3UCT^SCJ\.2[
MFP=EG'TT*:6;_P"S+.?I^Z4:;Q<>3(\31KNYL_\`@XZCR=A-WLOH_M.QS;>T
M"<OSD@>C9%[V7OX-!_QEU];1UZ51NBP5/O\`-%$"?.%_V2_I!J7B9C=I"&D(
M:0AI"&D(:0AI"&D(:0CE1_;D?JR7UPNO1CS8MU\4O_H'$O\`WG,?\D3U,T^_
MS?#$M4;O/\$0O:F(EH:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0
MAI"&D(:0B[+H<_*BQC]7GOYOR.I2I_*(\BO>$13ZZ?PA[\1E^/Y^7FC_`%+X
M_P#^,L&MB?A6_EXK_'5^.Y&LKQ@_S'1_IT_B-Q"&!^)?1`0+Y-Q#<!$1$-P$
M!#??R:R@;7V>?`$+$L=WDC%`F:B>,O<E]Z*RQF?,A0D]B6QQ#F*8O\+UH*G3
M4DHM$6`PZ[N8=RZ<PT$VTBK/'G7(.CB8AC`IN42B`#JE7=)VM^BK:)S.17K;
M6ZK#--I25)EA+:D;1NXQ5U-K"Y,/4SK:6_\`*)(0.M(YAE,\9[.$H,LSOXAQ
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MF\0V1;^U9U9VBG>;5#(R:23FR'-,G77CW*LNNNJT1.@CZP)5"@`E#4M0Z&HK
M>MM=/558#"7`T)HDUVJ0E12,FW*``53D!+C'=<=;/7-*@_2TH4XI*G".TFYD
M5F2E1S[`<<);3&Q/J:O+8&$8TKM%84IA2;%CSX.&L0_&H/*K;9E&QV!H]!>6
M6FU7;ZP-DG97!7A5$#I%*GRDW`>D<O;3V)2Z]4+JS4=MVQRYPL8"4DA.`P]7
M9$TCF'<6:CM:9FG;IRT&RT,^0I``QFHJ_P#=%#[!-ISDN[E6T'!UI)R5),D-
M6FKAE#-$T4DDBE;-W3M\X$QNZ`QSJ*G,HIN81W'5;4#+EOIQ3MNN+2!*:I3/
ME(`B@KK<E71\O.-H09[$YI?^XF/A:FU.%2`@@8;]\><I05@`!#77'&&D(:0C
M(N]F]_*/ZAOZD8?^?<9K$?Q>_P`)6K]XJ_0KC-?P3_Q?=_W:/TS<9A6L`8V/
MPTA#2$:;!OOL&_9OMQVU&9V;HAE3FS2&;C&@E*/:4!^6&N)`)!(Q&R(%*5`@
M@$&-O=)</I9.'$/1#MX\?].N>97$Q%*4I`2D`)!PC3N@WW$I1#??;;R^0>SM
M#7``#$;X*`49JQ(C?R$`.4"%`OF`H`'N;;:B0#MB()&S"'*4/U(>Y^CJ,S$`
ME(3E`ZL<9$$R_J">3;8H</\`1J``"BH>L=IXP6E*U!:P"H;"=L<G(0`V`I=@
MX;;!MMH"1L@0"22,3MZ9[8"0@@!1*78`V`-@V`/-MYM1F9SWQ%/4&5&"0)81
MQ]R0!]$A"@(B)@``#<1$1,.P!VCS#J!Q&4[(X);0@DI`!5MEO\L<G(4.PH>X
M'FV_2TV1SX#ALC3NT^'H%X;@'HAP`1W$/T1U&9G/?!0"_6QF9^>-.Y2$>84R
M".PAORAOL/$0WV[!'4(@$@;!&O=I[<O(780V$-@VV\VDSFS_`!N,1&"LX]:<
MY],:=TG^L+[@>3@&HYE3G/&(%(4,JA,3G`4RCML4H"'R`^9J`ZNS"(C#9#NR
M<H%$A1``VVV#;Y.H91.<L8@4I4CLU":.&Z->[)Q#D+Q[>`<=<LRN,1&$I;A(
M=`CC433WW$I?(/8':&_'CV<!UQ*RB0&$S$%#."E763*4MH\L0U^*YXB5CZ4X
MK'N`NF^!_#[K*ZB7GO!B>J-VI),*NR?N"Q);I*18F*1XZ,_4%&+;+"5NHNFJ
MLN/<-U`-2NJ-1NVS);*,%=WJ.JV![JCY)X=,9;>%7PZ6GFE75NO>8=5]%<G-
M.([6O>'4-0I,RFF0O#$R)<(.`*1M((\#T!^#G3<-S9.IGK*DB=376+;G2-GL
M5GO#C\+*S09UZ5)4S.MLY,AVDS-QIS=W[[.$C`ER\K%)LD4O-UV/25/1'OM[
M*:J\N3)4X`K+T)GP,L?1%1>('Q@WC6-%_P".^43"],<G*-`9:IJ4]BY5(!RA
M3ZFY$I5M+>^8*B3,1!5T00!^J?VA/(&1&9`D:U0\WY[RHLY32`[9&&I/OS3:
MJLJ<.\("02[J.(@8!#<_*(<-4-9T"Z\QWZND)324ZBJ0V`A.4"0PG,^D1GIS
MR?<Y6>SLM.F*U7^=N%NH*5$C)155+%6X3O.1+2@=_6/&,Z@J1>42F(4=QX@(
M`._``$1\G$>.KT@D',/6C1JDE/JX2C?W2?\`],G9M\Z'9V;=G9L.F97$QQRI
M.T;Y^?CY8<A````I0`.P``.&^DS`@$YCZT:=RE_],GG'T0X\=^/GV'4./3MZ
M8B0"9G$F7N;(W%(0H;%*4`#S``:@0%$$XD;(B229G;#D*([\H;[;;[!OMOOM
M\K<=1)F)'9$-V7XLYQQBB3?<"$`>(".W$0'R;[=F^HDE6W&($`J"CZP@5$@"
M(\A-Q`0W`H;\1`1X[>74!@)#9'+,KB8&23VW!,NY2B!>`=G:(!YM]M<LRC@3
M@8@I:@DG:=OG`P\\1R>*WU&*=+705U"Y.BWA8ZVO:>ICZC'`2E4"XY&4+5HM
MRAQ`07C&[Y=X&P[_`.Z[AQ`-4_J>X?1=D>JEGXI`,Y&9P&/GB_OA7Y>/<U^?
MNGM*K2%4J:I-2\%#,GL:8=X4E0.&59;#1GAUY=$02^S!]+*:;#-G6#8(\5%W
M2B>$<:NW2('$J+7U&Q9(E6CA0O>`=9V>-9`H40'E27*/:(:H3E=:'6FJJ\._
M]565)GC(8GTGWHSQ]I]S0;776+DI;'"*>FIS7UB4GJYU$M4[*A_]8"U)21(9
MDD=&7UL&P!MPV\NW_AJ[()VQJ0RIEEEU8X10)N(@0@!S`;L#YX.(&[.T!XA\
MG7(J4=I,1W!.X"0Z(AZZZ_!4Z0>MR<DL@/XV4PSF20V.^R5C%*.9C8W(DY>_
MNE4>-C05E=&Y0$SO9M('VV,X$-M4E=M#V2\9GE)+-2H8J1@/*4[">)\YC+;D
M;XV><G(AA%GHGD7C2*`4MT5:5%#,YX,O@YVQ,S")E(V!(B&]'V5Z;]_.Z<=9
MD4:N@X,<3HX>>DG!:\P\I.Y->S,2.0#8!^F"0.WE\FJ*1RF9[8J%8ONT\<!/
MS;HS2=]JL7+(E!TC.^I1,E54>[3_``@GM)=!B:OH4\&[I$Z&)%E<ZO"2&4\S
M-`$4LM9+%C)3,-WH<BOX&P+1NE`5(!*)B@N@DH_$HB4S@0$0U6UDT;8[&LO4
MZ%.U)`!4YUI2WIGL)WRC![G?XQ.;W/=E=LO;XMNC5JPH:0E#*MDNV4#G>`E,
M!?5!,Y1+5W)`0%+;T1)RB'Z`!V[=O#MU54@#,#$QBIV*>R['XLI>;AZ,(I%E
M[^#0?\9=?6T=2U1NB=I]_FBB!/G"_P"R7](-2\3,;M(0TA#2$-(0TA#2$-(0
MTA#2$<J/[<C]62^N%UZ,>;%NOBE_]`XE_P"\YC_DB>IFGW^;X8EJC=Y_@B%[
M4Q$M#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$79=#G
MY46,?J\[_-^1U*5/Y1'D5[PCDGUA^$/?B,OQ_>'7FCOP_P#9;'_;P_\`O+!K
M8GX5<>7BI?\`SJ_'<C65XP0?_(Z!+'NZ?Q&XA`UDWF3Q$8H]DY\E7H,![/T?
MFZ9D\1'-#;@VI5Z#&FX^<?\`3J.=/$1V=FOY)]$;_2\X[?+U#.CB(ZSVVS*?
M08TY1^3[NF='$0^>^2KT&'*/R?=TSHXB'SWR5>@QIIF3Q$<.R=^2KT&&F9/$
M0[)WY*O08:9D\1#LG?DJ]!AIF3Q$.R=^2KT&&F9/$1!2%)]8$>6,B_V;[\H_
MJ&_J1A_Y]QFL2/%X0=)6J1'_`.BK]"N,U?!/_%]W_=H_3-1F$ZP"C8_#2$-(
M0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(1P*!N?B`[`3B
M.^Q=MQW`=04D$)/!4)*'70>M.4HQ4>M?(D)T9^.WA3JIZBHI\7I_O.&&M,IE
M^.P=RD31+`UKLI6I>0`J+=<Y5H&3>BNZ30*9=-I*F<%(;8P#;:_.-6S7%-=[
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MS.>NTVL5\L@H!54&Z#<IP`YCEU*:#L-5;6GKA685E4K,OR;0#P)VX14WM`?$
M%8N9FL*#EKH1U#NB].)R%QLGLWJA*0TK)C(I82,@(VE2MLIG(Z+OMZ7;O\C_
M`%:N'&O2-=(0TA#2$-(0TA#2$-(1H;L'7%9DDF$1E^*9T'3GB$=.3#"%=R4T
MQA)1>2*WD)O-2D*\L$,^&$CYV*5B):.8/HYZHW60G3+)&36`2N$2;AR[[>%J
MFQKU);10!>1,QCY(R&\+_/MKPV<RE<PZF@^E*5="Y3=D%9"`XI*YA4L.L@8[
M<I(GNBO71)TMU_HTZ:L8].U;D1G&^/H=TG*V0S!.*6M5DFI5[-6&R.(Y)9<&
MIY"1>FY$Q44,1$I"B8PAN,W9K8+)96[>C'(F0.T^<^>*#YR<T+OSIYH7?F9=
M6BP+H\E:609Y$MH2A"0=H`2D3E@53.,7=Z],;(MK#481L$A1,!A#B'9Q']+L
MTQ\T<@H@$#88`F0-]@VW[=N&^H22=P]$=80D>J)>3"->4-]^/NCHD9=D<YF4
MHW:C$(I'E=JZ=(0A&S9PX$'#L3=P@JL!`[M'83]T0XE`?)OJ7?!,I1,4Y`G/
MHBC!8F5`I0]ZY'@4/_L77F^I:E\JN!B8S)XB-?>J5^UDC_(77[UIE5P,,R>(
MA[U2OVLD?Y"Z_>M,JN!AF3Q$/>J5^UDC_(77[UIE5P,,R>(A[U2OVLD?Y"Z_
M>M,JN!AF3Q$/>J5^UDC_`"%U^]:95<##,GB(>]4K]K)'^0NOWK3*K@89D\1#
MWJE?M9(_R%U^]:95<##,GB(>]4K]K)'^0NOWK3*K@89D\1#WJE?M9(_R%U^]
M:95<##,GB(Y$HN4!5(1C)'8%4Q'_`'%UV`<HC_Y7FUZ$>?%`/$SK=CL=%Q6C
M7:].V!9O;I9=RC!0\C+JMDCPR9"*.4XYLY.@0Q^`&,``(\-]3#!`G/HB7?!,
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M$>W6FQ7?RE6G8YB@!X*0(3OG;M@BW2YCF``YC!N(@';J4J""X@C@KWHYMI4"
M)@[1$<?CLX@RW=^MYO,TO%>2KA#AARAM!EZK1+588OUM!W/"NU]\(B)>,_64
M0.'.GS\Y>8-P#<-;`/#!?K';=!K8N-;24[_;J.5UYMM7K.;E*!W\(US^+'3F
MH+KS%146NAK*FG#"1F:9<6F>1O#,E)&[C$,G]W3J'^(#-_\`9-D'^CVLEOMG
MHGZRMO[2S^LC%[["ZY^J[E^S/_JX?W=.H?X@,X?V39!_H]J/VST3]96W]I8_
M61'["ZZ^J[E^S/\`ZN']W3J'^(#.']DV0?Z/:?;/1/UE;?VEC]9#["ZZ^J[E
M^S/_`*N-/[N?4-_A_P`W_P!DV0/Z/:?;/1/UE;?VEG]9#["ZZ^K+E^S/_JX?
MW<^H;_#_`)O_`+)L@?T>T^V>BOK*W?M+/ZR'V%UU]67+]F?_`%</[N?4-_A_
MS?\`V39`_H]I]L]%?65N_:6?UD/L+KKZLN7[,_\`JXU_NZ=0_P`0&</[)L@_
MT>T^V>B?K*V_M+'ZR'V%UU]5W+]F?_5P_NZ=0_Q`9P_LFR#_`$>T^V>B?K*V
M_M+'ZR'V%UU]5W+]F?\`U</[NG4/\0&</[)L@_T>T^V>B?K*V_M+'ZR'V%UU
M]5W+]F?_`%</[NG4/\0&</[)L@_T>T^V>B?K*V_M+'ZR'V%UU]5W+]F?_5P_
MNZ]0X?\`]`9O_LER`/\`_'M0^V6B?K*V_M+/ZR(?8'7#F"K7<OV9_P#5QD">
MSU8OR?1.H3/;^]8TR#2&#[#42T8OKA2[)6&;UV6[QRQFC1S-QC%)RY(B03B0
M@B8"@([;!K%/Q97W3]UTI:VK154M0\FXJ*@TZVX0GL5"9"%*($]YPC,'P>::
MOUCU9=7;O1U5,TNW`)+K3C8)[9LR!6E()D"9",L[6"$;!8:0AI"&D(:0AI"&
MD(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"-IB\P;;B'RM1!E$")D&<B
M#.*+YNZ=<)=2-&>8VSKC:K9.I3U8KH\):8U)Z1J^3+RHR46\+W<A#R:!>!'#
M55%8`X<VW#4I645+7TYIJMM*VE;08JK16MM6\NKP+_HBX55MNN8$K964YI2.
M5:?56B8GE6".B+7,)>%)X?73S;&5ZQ;TRT:+N,8L+B)L4\M/7>1AUQ'F!>(-
M=)>?1BW"9@`2*($343V]$P:\FDTM8:%P.TM,TEP;Y3/NQ=;7GBEY_<R;8;-J
M[4U>_:5#*IE'9L(6GY+@80WG`X+G$@B34J(@)3G'83"/-RB)A'RF$"@(B&VJ
MA)Q)X@"6[",?4MH1,-C+-68]).W;QP)\@CLZA'.&D(:0AI"&D(:0AI"&D(:0
MVQMY0^3_`..N)2HF>8Q```91LC9W1./R>WLX^X&HI"DF943Y8Y9E@``D2CE[
M.&HQ"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI
M"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(
M:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI
M"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(
..:0AI"&D(:0AI"&D(_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
